data_2nc7_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2nc7 _Structure_validation_residue.Date_analyzed 2017-04-14 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.209 0.528 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.35 -45.44 24.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.436 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 175.27 131.27 1.41 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.471 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -127.67 105.64 8.6 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.816 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.582 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.25 111.4 20.89 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.867 0.841 . . . . 0.0 109.211 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -147.98 119.97 8.22 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.022 0.915 . . . . 0.0 110.234 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.55 160.94 11.3 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -178.506 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.6 t -147.17 119.13 8.16 Favored 'General case' 0 C--N 1.269 -2.927 0 CA-C-O 122.536 1.16 . . . . 0.0 111.449 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.572 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.51 136.69 29.5 Favored Pre-proline 0 C--N 1.293 -1.852 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.415 -179.194 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.54 -14.1 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 122.885 0.94 . . . . 0.0 110.363 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.445 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -84.51 -27.85 27.13 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.171 0.986 . . . . 0.0 109.371 177.488 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.572 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 40.8 p90 -172.95 159.43 4.04 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -178.733 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.473 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.4 OUTLIER -170.67 131.46 0.88 Allowed 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 116.565 -2.054 . . . . 0.0 110.453 178.641 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -162.75 155.9 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-O 121.631 0.729 . . . . 0.0 110.128 -179.403 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.0 OUTLIER -129.35 128.51 43.24 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.366 0.603 . . . . 0.0 110.141 -179.88 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.412 ' CG1' ' NH2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -165.02 136.77 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-O 122.019 0.914 . . . . 0.0 109.692 179.774 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.07 107.19 0.28 Allowed Glycine 0 C--N 1.292 -1.914 0 N-CA-C 107.888 -2.085 . . . . 0.0 107.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.414 ' N ' ' HD2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.157 -1.417 . . . . 0.0 111.327 -179.039 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.7 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.102 0.477 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.67 -29.24 4.22 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.445 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -163.7 122.32 1.08 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.465 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -129.59 104.86 7.69 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.793 -1.163 . . . . 0.0 107.885 177.903 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.573 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.93 111.17 20.02 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -147.09 120.89 9.25 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-O 122.084 0.945 . . . . 0.0 110.259 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.02 160.33 11.94 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.684 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 t -149.64 117.99 6.46 Favored 'General case' 0 C--N 1.267 -2.987 0 CA-C-O 122.619 1.2 . . . . 0.0 111.552 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.83 136.88 29.84 Favored Pre-proline 0 C--N 1.293 -1.885 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.126 -179.322 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.83 -15.58 7.23 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 122.792 0.891 . . . . 0.0 110.336 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.464 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 51.8 mtp180 -82.38 -28.36 31.54 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 122.131 0.967 . . . . 0.0 109.511 177.496 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.566 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.0 p90 -173.15 159.77 3.96 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -178.766 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.468 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.2 OUTLIER -171.29 131.85 0.78 Allowed 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 116.634 -2.026 . . . . 0.0 110.389 178.534 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -162.95 156.65 2.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.703 0.763 . . . . 0.0 110.243 -179.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -131.48 123.28 27.74 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.454 0.645 . . . . 0.0 110.215 -179.996 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 85.0 t -153.66 123.64 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.85 105.21 0.23 Allowed Glycine 0 C--N 1.297 -1.629 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.423 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.789 0 C-N-CA 118.454 -1.298 . . . . 0.0 111.086 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . 0.445 ' HB3' ' HD3' ' A' ' 4' ' ' ARG . 8.3 tpp180 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.234 0.54 . . . . 0.0 110.165 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.35 -35.76 82.94 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.1 121.97 1.23 Allowed Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.564 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -142.15 106.95 4.88 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.729 -1.188 . . . . 0.0 109.373 177.815 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.54 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 1.8 mm? -112.94 113.14 25.07 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.87 120.91 9.4 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-O 121.961 0.886 . . . . 0.0 110.237 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.0 160.27 11.93 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -178.675 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 t -148.34 118.59 7.3 Favored 'General case' 0 C--N 1.266 -3.023 0 CA-C-O 122.507 1.146 . . . . 0.0 111.626 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.567 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.7 136.39 28.68 Favored Pre-proline 0 C--N 1.292 -1.92 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.388 -179.37 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.46 -14.24 6.7 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 122.78 0.884 . . . . 0.0 110.259 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.532 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 20.1 mmm-85 -85.12 -26.99 26.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.983 0.897 . . . . 0.0 109.55 177.529 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.567 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.252 40.4 p90 -173.43 159.69 3.75 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -178.99 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.435 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.88 132.55 0.88 Allowed 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 116.586 -2.045 . . . . 0.0 110.336 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -163.08 156.67 2.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-O 121.736 0.779 . . . . 0.0 110.361 -179.191 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -130.98 123.9 29.82 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.419 0.628 . . . . 0.0 110.161 179.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 86.5 t -154.23 126.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 CA-C-O 121.622 0.725 . . . . 0.0 109.155 179.689 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.427 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.5 105.57 0.25 Allowed Glycine 0 C--N 1.295 -1.726 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.472 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.872 0 C-N-CA 118.516 -1.274 . . . . 0.0 111.379 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.177 0.513 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.99 -23.86 7.2 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -131.6 106.46 0.67 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.45 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -128.5 104.74 7.86 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 118.728 -1.189 . . . . 0.0 107.876 177.763 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.586 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.98 109.94 17.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.813 0.816 . . . . 0.0 108.808 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 53.7 t -156.57 120.5 4.35 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-O 122.389 1.09 . . . . 0.0 110.474 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.35 161.03 9.78 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 4.8 t -142.12 118.97 11.17 Favored 'General case' 0 C--N 1.267 -3.0 0 CA-C-O 122.414 1.102 . . . . 0.0 111.148 -179.725 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.526 ' HG3' ' CZ ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -137.81 137.97 22.81 Favored Pre-proline 0 C--N 1.29 -1.985 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.41 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -50.77 -17.8 3.52 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 122.727 0.856 . . . . 0.0 110.801 -178.284 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.506 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 17.2 mmm-85 -73.85 -34.54 64.55 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.122 0.963 . . . . 0.0 109.118 177.141 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.526 ' CZ ' ' HG3' ' A' ' 9' ' ' ARG 0.255 40.7 p90 -174.09 162.33 3.76 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -178.788 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.417 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 0.6 OUTLIER -168.47 125.48 1.04 Allowed 'General case' 0 C--N 1.29 -2.01 0 C-N-CA 116.868 -1.933 . . . . 0.0 110.585 178.351 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.417 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.43 156.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.704 -0.623 . . . . 0.0 109.877 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' HA ' ' HA ' ' A' ' 6' ' ' CYS . 35.9 m -135.68 118.07 15.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.494 -0.754 . . . . 0.0 110.878 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.41 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 75.4 t -155.51 123.51 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.421 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.6 107.17 0.29 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.902 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.373 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.263 0.554 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.15 69.89 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.464 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 149.02 126.86 1.54 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.593 ' HA ' ' HA3' ' A' ' 17' ' ' GLY . 0.0 OUTLIER -131.57 103.96 6.69 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.694 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.99 111.38 18.87 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 48.7 t -152.84 123.12 7.12 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.37 1.081 . . . . 0.0 110.598 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.42 161.02 11.63 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 -178.753 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.1 t -145.08 118.82 9.21 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-O 122.521 1.153 . . . . 0.0 111.779 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.551 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.53 136.18 28.56 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.181 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.45 -13.2 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 122.791 0.89 . . . . 0.0 110.359 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.534 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 8.1 mmm-85 -85.67 -27.11 25.58 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.134 0.968 . . . . 0.0 109.577 177.525 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.551 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.253 40.1 p90 -173.53 159.81 3.71 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 -179.077 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.427 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.87 129.32 0.78 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.624 -2.03 . . . . 0.0 110.5 178.767 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.44 155.41 2.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 121.46 0.648 . . . . 0.0 109.981 -179.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 6' ' ' CYS . 18.6 m -137.2 117.72 13.83 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.635 -0.665 . . . . 0.0 110.523 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 96.0 t -153.02 121.2 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.564 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.593 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -168.16 106.56 0.26 Allowed Glycine 0 C--N 1.297 -1.603 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.423 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.339 -1.344 . . . . 0.0 111.126 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 121.224 0.535 . . . . 0.0 110.166 . . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.35 -11.1 83.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.419 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -158.52 120.43 0.97 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.484 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -127.25 105.55 8.62 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 177.76 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.4 110.95 20.09 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.879 0.847 . . . . 0.0 109.066 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.31 120.71 8.46 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.181 0.991 . . . . 0.0 110.092 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.25 159.83 11.08 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -149.65 119.35 7.02 Favored 'General case' 0 C--N 1.268 -2.958 0 CA-C-O 122.598 1.189 . . . . 0.0 111.379 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.553 ' HB2' ' CE1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.7 136.6 29.22 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.953 -1.022 . . . . 0.0 109.28 -179.242 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -54.52 -12.88 4.72 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.92 0.958 . . . . 0.0 110.634 -179.317 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.435 ' N ' ' HD3' ' A' ' 11' ' ' ARG . 0.0 OUTLIER -87.53 -25.91 23.43 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 109.406 177.667 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.553 ' CE1' ' HB2' ' A' ' 9' ' ' ARG 0.256 40.3 p90 -173.61 159.69 3.62 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 -178.95 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.42 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.6 OUTLIER -170.13 133.31 1.13 Allowed 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 116.725 -1.99 . . . . 0.0 110.733 178.647 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -158.62 156.02 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 CA-C-O 121.766 0.793 . . . . 0.0 110.327 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -136.62 126.58 25.93 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.398 0.618 . . . . 0.0 110.273 179.787 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -165.3 138.19 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 CA-C-O 121.962 0.887 . . . . 0.0 109.649 179.676 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.0 105.62 0.25 Allowed Glycine 0 C--N 1.29 -2.006 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.442 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.846 0 C-N-CA 118.471 -1.292 . . . . 0.0 111.359 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.043 0.449 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.73 -29.83 0.49 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.455 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -155.79 118.67 0.86 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.467 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -129.58 105.12 7.85 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 118.765 -1.174 . . . . 0.0 107.919 177.945 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.575 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.61 111.38 20.58 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.942 0.877 . . . . 0.0 108.664 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -146.93 120.55 9.15 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-O 122.02 0.914 . . . . 0.0 110.245 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.23 160.33 11.5 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 t -148.23 118.34 7.25 Favored 'General case' 0 C--N 1.266 -3.046 0 CA-C-O 122.574 1.178 . . . . 0.0 111.457 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.561 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.59 136.9 29.83 Favored Pre-proline 0 C--N 1.292 -1.898 0 CA-C-N 114.821 -1.082 . . . . 0.0 109.301 -179.307 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -54.04 -15.48 7.65 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 122.785 0.887 . . . . 0.0 110.252 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.471 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 63.3 mtp180 -82.91 -28.22 30.1 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 122.148 0.975 . . . . 0.0 109.575 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.561 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.3 p90 -173.21 159.9 3.95 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -178.769 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.457 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.91 131.25 0.82 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.677 -2.009 . . . . 0.0 110.457 178.592 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 t -163.1 156.82 2.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-O 121.847 0.832 . . . . 0.0 110.324 -179.262 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -130.9 122.83 27.69 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.671 -0.643 . . . . 0.0 110.072 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 99.3 t -153.8 123.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.562 0.696 . . . . 0.0 109.386 179.717 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.2 106.18 0.26 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.82 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.544 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.793 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.239 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.247 0.546 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.09 -0.89 6.91 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.455 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 180.0 129.57 1.36 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.465 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -128.98 104.87 7.84 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.7 -1.2 . . . . 0.0 107.912 178.23 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.571 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.01 111.36 20.23 Favored 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.1 t -150.22 122.2 8.22 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-O 122.154 0.978 . . . . 0.0 110.274 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.79 160.33 12.41 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 t -147.4 118.64 7.8 Favored 'General case' 0 C--N 1.266 -3.027 0 CA-C-O 122.463 1.125 . . . . 0.0 111.462 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.26 136.54 29.04 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.263 -179.102 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.4 -14.83 7.49 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 122.84 0.916 . . . . 0.0 110.227 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.545 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.3 mmm180 -84.79 -26.47 27.5 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 122.021 0.915 . . . . 0.0 109.587 177.621 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.566 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.252 42.0 p90 -173.74 160.09 3.62 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.027 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.419 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.6 131.02 0.88 Allowed 'General case' 0 C--N 1.288 -2.072 0 C-N-CA 116.609 -2.036 . . . . 0.0 110.53 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 t -163.47 156.72 2.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.666 0.746 . . . . 0.0 110.28 -179.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.45 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 38.7 t -133.07 131.36 40.51 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.616 0.722 . . . . 0.0 110.304 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.45 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 76.1 t -157.01 128.28 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 121.644 0.735 . . . . 0.0 109.049 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.34 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.752 0 N-CA-C 108.121 -1.991 . . . . 0.0 108.121 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.445 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.828 0 C-N-CA 118.443 -1.303 . . . . 0.0 111.383 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 1.7 tpp85 . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.185 0.517 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.22 -11.86 17.03 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.443 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.18 114.78 0.71 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.469 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -129.82 104.67 7.53 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 118.679 -1.209 . . . . 0.0 107.95 177.9 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.58 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.64 110.57 18.68 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.5 t -154.99 122.33 5.6 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.343 1.068 . . . . 0.0 110.657 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.56 161.03 11.34 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.278 -1.379 . . . . 0.0 107.278 -178.661 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.5 t -142.24 119.06 11.16 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.542 1.163 . . . . 0.0 111.687 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.545 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.89 136.62 29.45 Favored Pre-proline 0 C--N 1.292 -1.915 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.138 -179.272 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -54.04 -14.91 6.71 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 122.767 0.877 . . . . 0.0 110.204 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.517 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 8.8 mmm-85 -83.88 -27.69 28.47 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.996 0.903 . . . . 0.0 109.594 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.545 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 42.3 p90 -173.62 160.55 3.79 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -178.864 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.416 ' O ' ' CG2' ' A' ' 14' ' ' VAL . 0.7 OUTLIER -170.32 127.36 0.81 Allowed 'General case' 0 C--N 1.288 -2.075 0 C-N-CA 116.815 -1.954 . . . . 0.0 110.487 178.482 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.416 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.31 156.11 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.592 -0.693 . . . . 0.0 110.111 -179.127 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.493 ' HA ' ' HA ' ' A' ' 6' ' ' CYS . 36.8 m -136.26 119.21 16.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.618 -0.676 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 94.5 t -153.1 123.68 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.58 -0.7 . . . . 0.0 109.231 179.654 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.08 108.78 0.34 Allowed Glycine 0 C--N 1.296 -1.668 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 -179.823 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.419 ' N ' ' HD2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.849 0 C-N-CA 118.04 -1.464 . . . . 0.0 111.345 -178.927 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.3 tpp85 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.21 0.529 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.07 -21.17 74.43 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.451 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 179.0 130.48 1.44 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.452 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -129.55 105.23 7.93 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.657 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.62 111.28 19.65 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-O 121.758 0.79 . . . . 0.0 108.913 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.0 t -150.19 121.06 7.61 Favored 'General case' 0 C--N 1.29 -2.008 0 CA-C-O 122.11 0.957 . . . . 0.0 110.511 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.75 160.95 10.88 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.642 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -145.08 118.32 8.94 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.514 1.149 . . . . 0.0 111.523 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.09 136.94 29.95 Favored Pre-proline 0 C--N 1.293 -1.882 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.269 -179.295 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -53.98 -16.8 9.67 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 122.811 0.9 . . . . 0.0 110.109 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.537 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 17.8 mmm-85 -81.12 -28.2 35.24 Favored 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 122.023 0.916 . . . . 0.0 109.378 177.45 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.569 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 39.6 p90 -173.72 159.94 3.6 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.964 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.446 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.1 128.79 0.89 Allowed 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 116.621 -2.032 . . . . 0.0 110.429 178.585 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.414 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 1.9 t -163.35 156.85 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 121.639 0.733 . . . . 0.0 110.276 -179.167 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.449 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 24.8 t -129.52 129.67 44.8 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 121.657 0.741 . . . . 0.0 110.387 179.526 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.449 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 55.4 t -157.72 124.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.24 105.5 0.24 Allowed Glycine 0 C--N 1.298 -1.567 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 179.84 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.428 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.825 0 C-N-CA 118.431 -1.307 . . . . 0.0 111.235 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.24 0.543 . . . . 0.0 110.203 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.1 -17.7 74.07 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.416 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 168.69 134.2 1.69 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.487 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -127.8 105.42 8.43 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.718 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.583 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -115.04 110.87 20.23 Favored 'General case' 0 C--N 1.289 -2.03 0 CA-C-O 121.879 0.847 . . . . 0.0 108.798 -179.67 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.86 121.21 8.43 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.137 0.97 . . . . 0.0 110.356 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.26 160.34 11.45 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -178.787 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -149.72 118.79 6.73 Favored 'General case' 0 C--N 1.267 -2.98 0 CA-C-O 122.592 1.187 . . . . 0.0 111.632 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.565 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.02 136.56 29.38 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.912 -1.04 . . . . 0.0 109.083 -179.422 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.41 -16.13 6.93 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 122.783 0.886 . . . . 0.0 110.461 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.461 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 73.6 mtp180 -81.74 -28.17 33.47 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 122.011 0.91 . . . . 0.0 109.651 177.478 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 39.9 p90 -173.2 160.02 3.98 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.422 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -171.07 133.6 0.89 Allowed 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 116.741 -1.984 . . . . 0.0 110.464 178.609 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -162.1 156.02 2.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.627 0.727 . . . . 0.0 110.158 -179.338 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -132.9 129.37 38.27 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.465 0.65 . . . . 0.0 110.323 -179.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.41 ' CG1' ' NH2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -163.99 133.82 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 CA-C-O 121.981 0.896 . . . . 0.0 109.493 179.59 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.14 107.16 0.27 Allowed Glycine 0 C--N 1.293 -1.82 0 N-CA-C 108.083 -2.007 . . . . 0.0 108.083 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.475 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.146 -1.422 . . . . 0.0 111.486 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.115 0.484 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.34 -24.28 0.87 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.448 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -151.75 117.21 0.81 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.477 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -127.54 106.08 8.93 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.985 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.576 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.18 111.61 21.26 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-O 121.981 0.896 . . . . 0.0 109.291 -179.369 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -147.25 119.59 8.39 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.139 0.971 . . . . 0.0 110.081 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.52 161.61 9.71 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.305 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -144.2 117.69 9.13 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.545 1.164 . . . . 0.0 111.504 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.587 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.73 29.61 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.192 -179.429 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -53.34 -17.96 9.91 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.707 0.846 . . . . 0.0 110.194 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.622 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmt180 -79.21 -28.64 42.58 Favored 'General case' 0 N--CA 1.491 1.577 0 CA-C-O 121.986 0.898 . . . . 0.0 109.439 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.622 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 42.3 p90 -173.51 159.82 3.72 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -179.146 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.76 128.8 0.78 Allowed 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 116.486 -2.086 . . . . 0.0 110.484 178.513 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.9 t -162.3 155.77 2.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.593 0.711 . . . . 0.0 110.027 -179.402 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -125.01 129.37 50.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.656 -0.652 . . . . 0.0 110.06 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -165.12 136.28 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.911 0.862 . . . . 0.0 109.64 179.773 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.09 105.55 0.24 Allowed Glycine 0 C--N 1.291 -1.943 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.442 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.567 -1.253 . . . . 0.0 111.393 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.259 0.552 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -103.74 -45.64 1.49 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.446 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -178.41 128.54 1.28 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.47 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -128.97 104.63 7.7 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 118.788 -1.165 . . . . 0.0 107.975 177.855 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.578 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.75 110.43 18.41 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-O 121.924 0.868 . . . . 0.0 108.844 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.45 119.64 8.31 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.14 0.972 . . . . 0.0 110.242 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.9 160.57 10.31 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 t -149.66 117.29 6.18 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-O 122.536 1.16 . . . . 0.0 111.578 -179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.559 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -130.16 137.17 30.27 Favored Pre-proline 0 C--N 1.291 -1.938 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.047 -179.483 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.39 -16.57 7.53 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 122.83 0.911 . . . . 0.0 110.251 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.523 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmm180 -80.45 -28.77 37.6 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 122.07 0.938 . . . . 0.0 109.49 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.559 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.5 p90 -173.41 159.86 3.8 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 -178.917 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.453 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -171.57 130.68 0.7 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 116.574 -2.05 . . . . 0.0 110.535 178.43 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 t -162.7 156.06 2.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.656 0.741 . . . . 0.0 110.022 -179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.403 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.73 119.46 20.38 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.495 0.664 . . . . 0.0 110.356 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.403 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 91.4 t -154.41 121.98 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.495 0.664 . . . . 0.0 109.224 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.412 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.73 107.66 0.3 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.406 ' N ' ' HD2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.818 0 C-N-CA 118.111 -1.436 . . . . 0.0 111.307 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.115 0.483 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.93 -33.23 86.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.452 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 169.25 134.21 1.7 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.466 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -128.97 105.07 7.96 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 177.953 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.585 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.74 111.15 20.13 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -150.12 120.9 7.57 Favored 'General case' 0 C--N 1.29 -2.009 0 CA-C-O 122.093 0.949 . . . . 0.0 110.428 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.37 160.74 11.55 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.6 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.2 t -145.26 118.74 9.06 Favored 'General case' 0 C--N 1.266 -3.033 0 CA-C-O 122.55 1.167 . . . . 0.0 111.41 -179.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.56 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.1 136.16 28.12 Favored Pre-proline 0 C--N 1.292 -1.932 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.309 -179.265 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -54.89 -13.18 5.77 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 122.791 0.89 . . . . 0.0 110.324 -179.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.53 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 3.2 mmm-85 -86.99 -26.36 23.82 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.046 0.927 . . . . 0.0 109.441 177.623 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.56 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.253 41.5 p90 -173.58 159.8 3.67 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.257 -1.757 . . . . 0.0 106.257 -179.168 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.46 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.4 OUTLIER -170.62 130.93 0.87 Allowed 'General case' 0 C--N 1.287 -2.118 0 C-N-CA 116.686 -2.005 . . . . 0.0 110.356 178.842 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.41 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 1.7 t -163.54 156.92 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.603 0.716 . . . . 0.0 110.342 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.454 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 36.6 t -131.76 129.62 40.82 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.656 0.741 . . . . 0.0 110.471 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.454 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 72.9 t -157.78 126.34 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 CA-C-O 121.556 0.693 . . . . 0.0 109.146 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.47 106.94 0.28 Allowed Glycine 0 C--N 1.297 -1.605 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 179.991 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.405 ' HD2' ' N ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.869 0 C-N-CA 118.173 -1.411 . . . . 0.0 111.387 -179.257 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.1 ttm180 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.172 0.511 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -128.01 4.87 6.9 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.456 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 161.97 131.65 1.24 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.456 ' HD3' ' C ' ' A' ' 3' ' ' GLY . 0.0 OUTLIER -129.88 104.89 7.64 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.807 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.577 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.2 111.07 19.66 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-O 121.851 0.834 . . . . 0.0 108.847 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.37 120.6 8.92 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-O 122.059 0.933 . . . . 0.0 110.181 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.34 160.62 11.51 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 t -149.76 118.35 6.55 Favored 'General case' 0 C--N 1.267 -3.003 0 CA-C-O 122.529 1.157 . . . . 0.0 111.576 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.554 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.79 29.69 Favored Pre-proline 0 C--N 1.292 -1.929 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.354 -179.296 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.01 -13.28 4.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 122.884 0.939 . . . . 0.0 110.575 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.422 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.2 OUTLIER -85.05 -27.92 26.02 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.114 0.959 . . . . 0.0 109.33 177.529 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.554 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.26 40.7 p90 -173.08 159.67 3.98 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.769 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.463 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.3 OUTLIER -171.37 132.01 0.77 Allowed 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 116.655 -2.018 . . . . 0.0 110.51 178.589 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.4 t -162.97 156.02 2.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.777 0.799 . . . . 0.0 110.271 -179.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -131.58 128.63 39.6 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.643 -0.661 . . . . 0.0 110.08 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.441 HG12 ' CZ ' ' A' ' 18' ' ' ARG . 0.4 OUTLIER -165.57 131.8 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.483 -0.76 . . . . 0.0 109.432 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.7 109.32 0.3 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 -179.651 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.544 ' C ' ' HD2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.763 0 C-N-CA 117.886 -1.525 . . . . 0.0 111.841 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.043 0.449 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.36 -30.79 2.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.456 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.4 115.09 0.72 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.462 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -129.21 104.76 7.72 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.727 -1.189 . . . . 0.0 108.154 178.138 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.591 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -116.17 110.85 19.38 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.58 120.38 9.27 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-O 122.02 0.914 . . . . 0.0 110.298 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.01 160.05 11.74 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.8 t -148.43 118.56 7.25 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-O 122.514 1.149 . . . . 0.0 111.565 -179.337 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.11 136.7 29.43 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.417 -179.309 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.72 -14.67 8.02 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 122.791 0.89 . . . . 0.0 110.105 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.549 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 28.7 mmm-85 -84.71 -26.46 27.67 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 122.099 0.952 . . . . 0.0 109.524 177.501 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.569 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.253 41.6 p90 -173.63 158.89 3.46 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -179.276 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.478 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.3 OUTLIER -171.34 130.98 0.74 Allowed 'General case' 0 C--N 1.289 -2.061 0 C-N-CA 116.554 -2.058 . . . . 0.0 110.595 178.789 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.6 t -163.11 156.43 2.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-O 121.746 0.784 . . . . 0.0 110.29 -179.503 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.453 ' C ' ' CG2' ' A' ' 16' ' ' VAL . 0.3 OUTLIER -131.73 118.99 20.71 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.456 0.646 . . . . 0.0 109.969 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.453 ' CG2' ' C ' ' A' ' 15' ' ' CYS . 0.3 OUTLIER -153.69 121.92 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.473 -0.767 . . . . 0.0 109.326 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.56 105.21 0.24 Allowed Glycine 0 C--N 1.298 -1.573 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.166 -1.414 . . . . 0.0 111.224 -178.888 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . 0.438 ' CB ' ' HD2' ' A' ' 4' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.198 0.523 . . . . 0.0 110.352 . . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.13 -61.53 1.26 Allowed Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.221 -1.552 . . . . 0.0 109.221 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.13 119.87 1.0 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.526 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -145.5 104.68 3.93 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.596 -1.242 . . . . 0.0 109.283 177.798 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.542 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 1.7 mm? -115.68 112.05 21.5 Favored 'General case' 0 C--N 1.291 -1.959 0 C-N-CA 119.612 -0.835 . . . . 0.0 108.867 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.72 119.62 8.16 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 122.07 0.938 . . . . 0.0 110.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.84 160.65 10.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.0 t -148.03 118.02 7.21 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 122.641 1.21 . . . . 0.0 111.401 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.19 136.86 29.82 Favored Pre-proline 0 C--N 1.293 -1.859 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.319 -179.169 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -17.2 9.36 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 122.747 0.867 . . . . 0.0 110.133 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.559 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.9 mmt85 -80.96 -28.1 35.76 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.981 0.896 . . . . 0.0 109.534 177.541 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.577 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.254 42.1 p90 -173.62 159.88 3.65 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.049 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.465 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.79 130.99 0.83 Allowed 'General case' 0 C--N 1.288 -2.067 0 C-N-CA 116.698 -2.001 . . . . 0.0 110.564 178.617 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 t -163.1 156.16 2.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 CA-C-O 121.663 0.744 . . . . 0.0 110.087 -179.404 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.427 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.36 119.69 21.05 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.524 0.678 . . . . 0.0 110.308 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.427 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 69.3 t -156.09 123.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.641 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.494 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -167.75 105.27 0.23 Allowed Glycine 0 C--N 1.299 -1.502 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.425 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.847 0 C-N-CA 118.404 -1.318 . . . . 0.0 111.112 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.123 0.487 . . . . 0.0 110.147 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.98 -27.3 5.18 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.415 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 170.32 135.42 1.91 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.497 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -125.85 105.21 8.78 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -114.42 111.04 20.81 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-O 121.859 0.837 . . . . 0.0 108.842 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -151.65 121.43 7.02 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.078 0.942 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -167.92 160.76 12.5 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 -178.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -144.3 118.81 9.7 Favored 'General case' 0 C--N 1.265 -3.067 0 CA-C-O 122.529 1.157 . . . . 0.0 111.429 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.558 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.99 136.71 29.6 Favored Pre-proline 0 C--N 1.292 -1.899 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.203 -179.135 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -54.03 -16.08 8.62 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 122.772 0.88 . . . . 0.0 110.104 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.454 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 66.9 mtp180 -82.36 -28.4 31.55 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 122.103 0.954 . . . . 0.0 109.54 177.414 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.558 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 40.0 p90 -173.11 160.07 4.05 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 -178.594 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.455 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.5 OUTLIER -170.14 128.13 0.87 Allowed 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 116.679 -2.009 . . . . 0.0 110.338 178.517 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.4 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 1.9 t -162.87 156.92 2.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 121.646 0.736 . . . . 0.0 110.574 -179.143 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.428 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 16.5 t -126.68 132.31 51.21 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.572 0.701 . . . . 0.0 110.128 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.428 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 92.3 t -156.15 131.94 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -164.35 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.453 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.834 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.393 -179.106 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.197 0.522 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -94.77 -33.3 6.76 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.449 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 166.59 127.86 0.93 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.449 ' HD3' ' C ' ' A' ' 3' ' ' GLY . 0.0 OUTLIER -130.29 104.52 7.33 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 177.522 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.579 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.95 110.93 18.31 Favored 'General case' 0 C--N 1.29 -2.003 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.1 t -153.5 122.03 6.29 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.435 1.112 . . . . 0.0 110.585 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.31 161.0 11.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.8 t -143.32 119.14 10.55 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-O 122.598 1.19 . . . . 0.0 111.757 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.562 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.05 136.31 28.99 Favored Pre-proline 0 C--N 1.292 -1.935 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.056 -179.341 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.95 -15.79 7.91 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 122.765 0.876 . . . . 0.0 110.142 -179.297 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.577 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 20.5 mmt85 -82.68 -27.31 31.36 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.978 0.894 . . . . 0.0 109.525 177.545 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.577 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 43.1 p90 -173.83 159.88 3.51 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -179.093 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.428 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.6 OUTLIER -170.14 127.68 0.85 Allowed 'General case' 0 C--N 1.289 -2.041 0 C-N-CA 116.642 -2.023 . . . . 0.0 110.569 178.593 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.421 ' CG2' ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.27 155.85 2.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-O 121.465 0.65 . . . . 0.0 110.116 -179.19 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 6' ' ' CYS . 23.7 m -135.86 119.24 16.81 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.563 -0.711 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 95.8 t -152.17 124.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 CA-C-O 121.65 0.738 . . . . 0.0 109.083 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.432 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.24 107.88 0.31 Allowed Glycine 0 C--N 1.295 -1.702 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.468 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.922 0 C-N-CA 118.392 -1.323 . . . . 0.0 111.664 -178.951 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.114 0.483 . . . . 0.0 110.198 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -61.94 -51.24 58.43 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' GLY . . . . . 0.445 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -179.35 130.36 1.51 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ARG . . . . . 0.471 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -128.39 105.23 8.18 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.673 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LEU . . . . . 0.587 ' CD2' ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.43 112.08 21.76 Favored 'General case' 0 C--N 1.291 -1.975 0 CA-C-O 121.922 0.868 . . . . 0.0 108.797 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 t -147.82 121.59 9.28 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 122.042 0.925 . . . . 0.0 110.221 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.42 160.16 13.02 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -178.633 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -149.77 118.87 6.73 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.554 1.168 . . . . 0.0 111.607 -179.252 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.16 136.54 29.32 Favored Pre-proline 0 C--N 1.293 -1.886 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.246 -179.377 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -16.68 8.45 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 122.726 0.856 . . . . 0.0 110.311 -179.263 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ARG . . . . . 0.475 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 27.0 mtp180 -81.28 -28.44 34.69 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 122.143 0.973 . . . . 0.0 109.54 177.522 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' PHE . . . . . 0.577 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.1 p90 -173.19 159.5 3.87 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' CYS . . . . . 0.482 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.2 OUTLIER -170.56 131.05 0.89 Allowed 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 116.577 -2.049 . . . . 0.0 110.571 178.657 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.5 t -163.92 156.47 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.711 0.767 . . . . 0.0 110.163 -179.308 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' CYS . . . . . 0.433 ' O ' ' CG2' ' A' ' 16' ' ' VAL . 48.9 t -133.48 131.2 39.59 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 121.592 0.71 . . . . 0.0 110.347 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . 0.433 ' CG2' ' O ' ' A' ' 15' ' ' CYS . 70.8 t -156.6 128.55 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.23 106.23 0.26 Allowed Glycine 0 C--N 1.295 -1.715 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ARG . . . . . 0.524 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.418 -1.313 . . . . 0.0 111.251 -179.28 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.209 0.528 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.35 -45.44 24.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 175.27 131.27 1.41 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.641 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.67 105.64 8.6 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.816 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.25 111.4 20.89 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.867 0.841 . . . . 0.0 109.211 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -147.98 119.97 8.22 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.022 0.915 . . . . 0.0 110.234 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.55 160.94 11.3 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -178.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.6 t -147.17 119.13 8.16 Favored 'General case' 0 C--N 1.269 -2.927 0 CA-C-O 122.536 1.16 . . . . 0.0 111.449 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.572 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.51 136.69 29.5 Favored Pre-proline 0 C--N 1.293 -1.852 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.415 -179.194 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.54 -14.1 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 122.885 0.94 . . . . 0.0 110.363 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.464 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -84.51 -27.85 27.13 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.171 0.986 . . . . 0.0 109.371 177.488 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.572 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 40.8 p90 -172.95 159.43 4.04 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -178.733 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.713 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.4 OUTLIER -170.67 131.46 0.88 Allowed 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 116.565 -2.054 . . . . 0.0 110.453 178.641 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.75 155.9 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-O 121.631 0.729 . . . . 0.0 110.128 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.527 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -129.35 128.51 43.24 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.366 0.603 . . . . 0.0 110.141 -179.88 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.809 HG12 ' NH2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -165.02 136.77 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-O 122.019 0.914 . . . . 0.0 109.692 179.774 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.07 107.19 0.28 Allowed Glycine 0 C--N 1.292 -1.914 0 N-CA-C 107.888 -2.085 . . . . 0.0 107.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.809 ' NH2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.157 -1.417 . . . . 0.0 111.327 -179.039 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.7 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.102 0.477 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.67 -29.24 4.22 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -163.7 122.32 1.08 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.647 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.59 104.86 7.69 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.793 -1.163 . . . . 0.0 107.885 177.903 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.811 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.93 111.17 20.02 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -147.09 120.89 9.25 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-O 122.084 0.945 . . . . 0.0 110.259 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.02 160.33 11.94 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.684 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 t -149.64 117.99 6.46 Favored 'General case' 0 C--N 1.267 -2.987 0 CA-C-O 122.619 1.2 . . . . 0.0 111.552 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.83 136.88 29.84 Favored Pre-proline 0 C--N 1.293 -1.885 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.126 -179.322 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.83 -15.58 7.23 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 122.792 0.891 . . . . 0.0 110.336 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.487 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 51.8 mtp180 -82.38 -28.36 31.54 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 122.131 0.967 . . . . 0.0 109.511 177.496 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.566 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.0 p90 -173.15 159.77 3.96 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -178.766 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.713 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.2 OUTLIER -171.29 131.85 0.78 Allowed 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 116.634 -2.026 . . . . 0.0 110.389 178.534 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.95 156.65 2.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.703 0.763 . . . . 0.0 110.243 -179.315 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -131.48 123.28 27.74 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.454 0.645 . . . . 0.0 110.215 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG13 ' NH1' ' A' ' 18' ' ' ARG . 85.0 t -153.66 123.64 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.85 105.21 0.23 Allowed Glycine 0 C--N 1.297 -1.629 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.532 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.789 0 C-N-CA 118.454 -1.298 . . . . 0.0 111.086 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ARG . . . . . 0.495 ' HB3' ' HD3' ' A' ' 4' ' ' ARG . 8.3 tpp180 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.234 0.54 . . . . 0.0 110.165 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.35 -35.76 82.94 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.1 121.97 1.23 Allowed Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.564 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -142.15 106.95 4.88 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.729 -1.188 . . . . 0.0 109.373 177.815 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.785 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.8 mm? -112.94 113.14 25.07 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.87 120.91 9.4 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-O 121.961 0.886 . . . . 0.0 110.237 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.0 160.27 11.93 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -178.675 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 t -148.34 118.59 7.3 Favored 'General case' 0 C--N 1.266 -3.023 0 CA-C-O 122.507 1.146 . . . . 0.0 111.626 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.567 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.7 136.39 28.68 Favored Pre-proline 0 C--N 1.292 -1.92 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.388 -179.37 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.46 -14.24 6.7 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 122.78 0.884 . . . . 0.0 110.259 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 20.1 mmm-85 -85.12 -26.99 26.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.983 0.897 . . . . 0.0 109.55 177.529 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.567 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.252 40.4 p90 -173.43 159.69 3.75 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -178.99 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.737 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.88 132.55 0.88 Allowed 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 116.586 -2.045 . . . . 0.0 110.336 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -163.08 156.67 2.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-O 121.736 0.779 . . . . 0.0 110.361 -179.191 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.499 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -130.98 123.9 29.82 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.419 0.628 . . . . 0.0 110.161 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.499 HG23 ' C ' ' A' ' 15' ' ' CYS . 86.5 t -154.23 126.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 CA-C-O 121.622 0.725 . . . . 0.0 109.155 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.5 105.57 0.25 Allowed Glycine 0 C--N 1.295 -1.726 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.446 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.872 0 C-N-CA 118.516 -1.274 . . . . 0.0 111.379 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.177 0.513 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.99 -23.86 7.2 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.42 ' N ' ' HD3' ' A' ' 4' ' ' ARG . . . -131.6 106.46 0.67 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.639 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.5 104.74 7.86 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 118.728 -1.189 . . . . 0.0 107.876 177.763 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.814 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.98 109.94 17.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.813 0.816 . . . . 0.0 108.808 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 53.7 t -156.57 120.5 4.35 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-O 122.389 1.09 . . . . 0.0 110.474 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.35 161.03 9.78 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.423 ' HA ' ' CB ' ' A' ' 13' ' ' CYS . 4.8 t -142.12 118.97 11.17 Favored 'General case' 0 C--N 1.267 -3.0 0 CA-C-O 122.414 1.102 . . . . 0.0 111.148 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.547 ' HG3' ' CZ ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -137.81 137.97 22.81 Favored Pre-proline 0 C--N 1.29 -1.985 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.41 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -50.77 -17.8 3.52 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 122.727 0.856 . . . . 0.0 110.801 -178.284 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.531 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 17.2 mmm-85 -73.85 -34.54 64.55 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.122 0.963 . . . . 0.0 109.118 177.141 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.547 ' CZ ' ' HG3' ' A' ' 9' ' ' ARG 0.255 40.7 p90 -174.09 162.33 3.76 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -178.788 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.756 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.6 OUTLIER -168.47 125.48 1.04 Allowed 'General case' 0 C--N 1.29 -2.01 0 C-N-CA 116.868 -1.933 . . . . 0.0 110.585 178.351 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.43 156.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.704 -0.623 . . . . 0.0 109.877 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' C ' HG23 ' A' ' 16' ' ' VAL . 35.9 m -135.68 118.07 15.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.494 -0.754 . . . . 0.0 110.878 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.506 HG23 ' C ' ' A' ' 15' ' ' CYS . 75.4 t -155.51 123.51 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.6 107.17 0.29 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.902 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.373 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.263 0.554 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.15 69.89 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 149.02 126.86 1.54 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.644 ' HA ' ' HA3' ' A' ' 17' ' ' GLY . 0.0 OUTLIER -131.57 103.96 6.69 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.694 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.813 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.99 111.38 18.87 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 48.7 t -152.84 123.12 7.12 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.37 1.081 . . . . 0.0 110.598 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.42 161.02 11.63 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 -178.753 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.1 t -145.08 118.82 9.21 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-O 122.521 1.153 . . . . 0.0 111.779 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.551 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.53 136.18 28.56 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.181 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.45 -13.2 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 122.791 0.89 . . . . 0.0 110.359 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.557 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 8.1 mmm-85 -85.67 -27.11 25.58 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.134 0.968 . . . . 0.0 109.577 177.525 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.557 ' CD2' ' HB2' ' A' ' 11' ' ' ARG 0.253 40.1 p90 -173.53 159.81 3.71 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 -179.077 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.774 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.87 129.32 0.78 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.624 -2.03 . . . . 0.0 110.5 178.767 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.44 155.41 2.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 121.46 0.648 . . . . 0.0 109.981 -179.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.495 ' C ' HG23 ' A' ' 16' ' ' VAL . 18.6 m -137.2 117.72 13.83 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.635 -0.665 . . . . 0.0 110.523 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.495 HG23 ' C ' ' A' ' 15' ' ' CYS . 96.0 t -153.02 121.2 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.644 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -168.16 106.56 0.26 Allowed Glycine 0 C--N 1.297 -1.603 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.433 ' NH2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.339 -1.344 . . . . 0.0 111.126 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 121.224 0.535 . . . . 0.0 110.166 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.35 -11.1 83.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.409 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -158.52 120.43 0.97 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.646 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.25 105.55 8.62 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 177.76 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.812 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.4 110.95 20.09 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.879 0.847 . . . . 0.0 109.066 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.31 120.71 8.46 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.181 0.991 . . . . 0.0 110.092 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.25 159.83 11.08 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -149.65 119.35 7.02 Favored 'General case' 0 C--N 1.268 -2.958 0 CA-C-O 122.598 1.189 . . . . 0.0 111.379 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.565 ' HB2' ' CE1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.7 136.6 29.22 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.953 -1.022 . . . . 0.0 109.28 -179.242 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -54.52 -12.88 4.72 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.92 0.958 . . . . 0.0 110.634 -179.317 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.427 ' HB3' ' HD2' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -87.53 -25.91 23.43 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 109.406 177.667 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' CE1' ' HB2' ' A' ' 9' ' ' ARG 0.256 40.3 p90 -173.61 159.69 3.62 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 -178.95 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.6 OUTLIER -170.13 133.31 1.13 Allowed 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 116.725 -1.99 . . . . 0.0 110.733 178.647 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -158.62 156.02 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 CA-C-O 121.766 0.793 . . . . 0.0 110.327 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.534 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -136.62 126.58 25.93 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.398 0.618 . . . . 0.0 110.273 179.787 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.534 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -165.3 138.19 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 CA-C-O 121.962 0.887 . . . . 0.0 109.649 179.676 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.0 105.62 0.25 Allowed Glycine 0 C--N 1.29 -2.006 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.438 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.846 0 C-N-CA 118.471 -1.292 . . . . 0.0 111.359 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.043 0.449 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.73 -29.83 0.49 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -155.79 118.67 0.86 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.644 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.58 105.12 7.85 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 118.765 -1.174 . . . . 0.0 107.919 177.945 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.81 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.61 111.38 20.58 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.942 0.877 . . . . 0.0 108.664 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -146.93 120.55 9.15 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-O 122.02 0.914 . . . . 0.0 110.245 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.23 160.33 11.5 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 t -148.23 118.34 7.25 Favored 'General case' 0 C--N 1.266 -3.046 0 CA-C-O 122.574 1.178 . . . . 0.0 111.457 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.561 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.59 136.9 29.83 Favored Pre-proline 0 C--N 1.292 -1.898 0 CA-C-N 114.821 -1.082 . . . . 0.0 109.301 -179.307 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -54.04 -15.48 7.65 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 122.785 0.887 . . . . 0.0 110.252 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.495 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 63.3 mtp180 -82.91 -28.22 30.1 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 122.148 0.975 . . . . 0.0 109.575 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.561 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.3 p90 -173.21 159.9 3.95 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -178.769 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.729 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.91 131.25 0.82 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.677 -2.009 . . . . 0.0 110.457 178.592 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.729 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.1 156.82 2.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-O 121.847 0.832 . . . . 0.0 110.324 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -130.9 122.83 27.69 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.671 -0.643 . . . . 0.0 110.072 -179.985 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 15' ' ' CYS . 99.3 t -153.8 123.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.562 0.696 . . . . 0.0 109.386 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.2 106.18 0.26 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.544 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.793 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.239 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.247 0.546 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.09 -0.89 6.91 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.443 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 180.0 129.57 1.36 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.64 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.98 104.87 7.84 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.7 -1.2 . . . . 0.0 107.912 178.23 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.01 111.36 20.23 Favored 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.1 t -150.22 122.2 8.22 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-O 122.154 0.978 . . . . 0.0 110.274 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.79 160.33 12.41 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 t -147.4 118.64 7.8 Favored 'General case' 0 C--N 1.266 -3.027 0 CA-C-O 122.463 1.125 . . . . 0.0 111.462 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.26 136.54 29.04 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.263 -179.102 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.4 -14.83 7.49 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 122.84 0.916 . . . . 0.0 110.227 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.572 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.3 mmm180 -84.79 -26.47 27.5 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 122.021 0.915 . . . . 0.0 109.587 177.621 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.572 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 42.0 p90 -173.74 160.09 3.62 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.027 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.6 131.02 0.88 Allowed 'General case' 0 C--N 1.288 -2.072 0 C-N-CA 116.609 -2.036 . . . . 0.0 110.53 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.47 156.72 2.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.666 0.746 . . . . 0.0 110.28 -179.171 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.517 ' O ' HG23 ' A' ' 16' ' ' VAL . 38.7 t -133.07 131.36 40.51 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.616 0.722 . . . . 0.0 110.304 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 15' ' ' CYS . 76.1 t -157.01 128.28 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 121.644 0.735 . . . . 0.0 109.049 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.34 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.752 0 N-CA-C 108.121 -1.991 . . . . 0.0 108.121 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.451 ' NH2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.828 0 C-N-CA 118.443 -1.303 . . . . 0.0 111.383 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 1.7 tpp85 . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.185 0.517 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.22 -11.86 17.03 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.433 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.18 114.78 0.71 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.652 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.82 104.67 7.53 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 118.679 -1.209 . . . . 0.0 107.95 177.9 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.823 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.64 110.57 18.68 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.5 t -154.99 122.33 5.6 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.343 1.068 . . . . 0.0 110.657 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.56 161.03 11.34 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.278 -1.379 . . . . 0.0 107.278 -178.661 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.5 t -142.24 119.06 11.16 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.542 1.163 . . . . 0.0 111.687 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.545 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.89 136.62 29.45 Favored Pre-proline 0 C--N 1.292 -1.915 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.138 -179.272 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -54.04 -14.91 6.71 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 122.767 0.877 . . . . 0.0 110.204 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.542 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 8.8 mmm-85 -83.88 -27.69 28.47 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.996 0.903 . . . . 0.0 109.594 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.545 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 42.3 p90 -173.62 160.55 3.79 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -178.864 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.761 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.7 OUTLIER -170.32 127.36 0.81 Allowed 'General case' 0 C--N 1.288 -2.075 0 C-N-CA 116.815 -1.954 . . . . 0.0 110.487 178.482 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.31 156.11 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.592 -0.693 . . . . 0.0 110.111 -179.127 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.48 ' C ' HG23 ' A' ' 16' ' ' VAL . 36.8 m -136.26 119.21 16.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.618 -0.676 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.48 HG23 ' C ' ' A' ' 15' ' ' CYS . 94.5 t -153.1 123.68 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.58 -0.7 . . . . 0.0 109.231 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.08 108.78 0.34 Allowed Glycine 0 C--N 1.296 -1.668 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.849 0 C-N-CA 118.04 -1.464 . . . . 0.0 111.345 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.3 tpp85 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.21 0.529 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.07 -21.17 74.43 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 179.0 130.48 1.44 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.648 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.55 105.23 7.93 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.657 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.816 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.62 111.28 19.65 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-O 121.758 0.79 . . . . 0.0 108.913 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.0 t -150.19 121.06 7.61 Favored 'General case' 0 C--N 1.29 -2.008 0 CA-C-O 122.11 0.957 . . . . 0.0 110.511 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.75 160.95 10.88 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.642 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -145.08 118.32 8.94 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.514 1.149 . . . . 0.0 111.523 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.09 136.94 29.95 Favored Pre-proline 0 C--N 1.293 -1.882 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.269 -179.295 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -53.98 -16.8 9.67 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 122.811 0.9 . . . . 0.0 110.109 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 17.8 mmm-85 -81.12 -28.2 35.24 Favored 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 122.023 0.916 . . . . 0.0 109.378 177.45 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.569 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 39.6 p90 -173.72 159.94 3.6 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.964 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.767 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.1 128.79 0.89 Allowed 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 116.621 -2.032 . . . . 0.0 110.429 178.585 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -163.35 156.85 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 121.639 0.733 . . . . 0.0 110.276 -179.167 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 16' ' ' VAL . 24.8 t -129.52 129.67 44.8 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 121.657 0.741 . . . . 0.0 110.387 179.526 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 15' ' ' CYS . 55.4 t -157.72 124.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -167.24 105.5 0.24 Allowed Glycine 0 C--N 1.298 -1.567 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.48 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.825 0 C-N-CA 118.431 -1.307 . . . . 0.0 111.235 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.24 0.543 . . . . 0.0 110.203 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.1 -17.7 74.07 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.405 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 168.69 134.2 1.69 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.656 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.8 105.42 8.43 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.718 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -115.04 110.87 20.23 Favored 'General case' 0 C--N 1.289 -2.03 0 CA-C-O 121.879 0.847 . . . . 0.0 108.798 -179.67 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.86 121.21 8.43 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.137 0.97 . . . . 0.0 110.356 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.26 160.34 11.45 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -178.787 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -149.72 118.79 6.73 Favored 'General case' 0 C--N 1.267 -2.98 0 CA-C-O 122.592 1.187 . . . . 0.0 111.632 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.565 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.02 136.56 29.38 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.912 -1.04 . . . . 0.0 109.083 -179.422 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.41 -16.13 6.93 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 122.783 0.886 . . . . 0.0 110.461 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 73.6 mtp180 -81.74 -28.17 33.47 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 122.011 0.91 . . . . 0.0 109.651 177.478 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 39.9 p90 -173.2 160.02 3.98 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -171.07 133.6 0.89 Allowed 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 116.741 -1.984 . . . . 0.0 110.464 178.609 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 13' ' ' CYS . 0.9 OUTLIER -162.1 156.02 2.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.627 0.727 . . . . 0.0 110.158 -179.338 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.9 129.37 38.27 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.465 0.65 . . . . 0.0 110.323 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -163.99 133.82 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 CA-C-O 121.981 0.896 . . . . 0.0 109.493 179.59 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.14 107.16 0.27 Allowed Glycine 0 C--N 1.293 -1.82 0 N-CA-C 108.083 -2.007 . . . . 0.0 108.083 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.475 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.146 -1.422 . . . . 0.0 111.486 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.115 0.484 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.34 -24.28 0.87 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -151.75 117.21 0.81 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.639 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.54 106.08 8.93 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.825 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.18 111.61 21.26 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-O 121.981 0.896 . . . . 0.0 109.291 -179.369 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -147.25 119.59 8.39 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.139 0.971 . . . . 0.0 110.081 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.52 161.61 9.71 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.305 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -144.2 117.69 9.13 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.545 1.164 . . . . 0.0 111.504 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.587 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.73 29.61 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.192 -179.429 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -53.34 -17.96 9.91 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.707 0.846 . . . . 0.0 110.194 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.647 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmt180 -79.21 -28.64 42.58 Favored 'General case' 0 N--CA 1.491 1.577 0 CA-C-O 121.986 0.898 . . . . 0.0 109.439 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.647 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 42.3 p90 -173.51 159.82 3.72 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -179.146 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.76 128.8 0.78 Allowed 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 116.486 -2.086 . . . . 0.0 110.484 178.513 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -162.3 155.77 2.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.593 0.711 . . . . 0.0 110.027 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -125.01 129.37 50.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.656 -0.652 . . . . 0.0 110.06 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -165.12 136.28 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.911 0.862 . . . . 0.0 109.64 179.773 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.09 105.55 0.24 Allowed Glycine 0 C--N 1.291 -1.943 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.442 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.567 -1.253 . . . . 0.0 111.393 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.259 0.552 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -103.74 -45.64 1.49 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.434 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -178.41 128.54 1.28 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.659 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.97 104.63 7.7 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 118.788 -1.165 . . . . 0.0 107.975 177.855 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.75 110.43 18.41 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-O 121.924 0.868 . . . . 0.0 108.844 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.45 119.64 8.31 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.14 0.972 . . . . 0.0 110.242 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.9 160.57 10.31 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HA ' ' CB ' ' A' ' 13' ' ' CYS . 7.8 t -149.66 117.29 6.18 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-O 122.536 1.16 . . . . 0.0 111.578 -179.788 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.559 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -130.16 137.17 30.27 Favored Pre-proline 0 C--N 1.291 -1.938 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.047 -179.483 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.39 -16.57 7.53 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 122.83 0.911 . . . . 0.0 110.251 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.547 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmm180 -80.45 -28.77 37.6 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 122.07 0.938 . . . . 0.0 109.49 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.559 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.5 p90 -173.41 159.86 3.8 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 -178.917 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -171.57 130.68 0.7 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 116.574 -2.05 . . . . 0.0 110.535 178.43 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.6 t -162.7 156.06 2.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.656 0.741 . . . . 0.0 110.022 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.73 119.46 20.38 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.495 0.664 . . . . 0.0 110.356 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG13 HH11 ' A' ' 18' ' ' ARG . 91.4 t -154.41 121.98 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.495 0.664 . . . . 0.0 109.224 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.73 107.66 0.3 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.532 HH11 HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.818 0 C-N-CA 118.111 -1.436 . . . . 0.0 111.307 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.115 0.483 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.93 -33.23 86.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.439 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 169.25 134.21 1.7 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.643 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.97 105.07 7.96 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 177.953 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.818 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.74 111.15 20.13 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -150.12 120.9 7.57 Favored 'General case' 0 C--N 1.29 -2.009 0 CA-C-O 122.093 0.949 . . . . 0.0 110.428 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.37 160.74 11.55 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.6 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.2 t -145.26 118.74 9.06 Favored 'General case' 0 C--N 1.266 -3.033 0 CA-C-O 122.55 1.167 . . . . 0.0 111.41 -179.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.1 136.16 28.12 Favored Pre-proline 0 C--N 1.292 -1.932 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.309 -179.265 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -54.89 -13.18 5.77 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 122.791 0.89 . . . . 0.0 110.324 -179.421 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 3.2 mmm-85 -86.99 -26.36 23.82 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.046 0.927 . . . . 0.0 109.441 177.623 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 9' ' ' ARG 0.253 41.5 p90 -173.58 159.8 3.67 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.257 -1.757 . . . . 0.0 106.257 -179.168 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.762 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.4 OUTLIER -170.62 130.93 0.87 Allowed 'General case' 0 C--N 1.287 -2.118 0 C-N-CA 116.686 -2.005 . . . . 0.0 110.356 178.842 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.7 t -163.54 156.92 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.603 0.716 . . . . 0.0 110.342 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.553 ' O ' HG23 ' A' ' 16' ' ' VAL . 36.6 t -131.76 129.62 40.82 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.656 0.741 . . . . 0.0 110.471 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.555 HG13 ' NH1' ' A' ' 18' ' ' ARG . 72.9 t -157.78 126.34 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 CA-C-O 121.556 0.693 . . . . 0.0 109.146 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.406 ' H ' ' HE ' ' A' ' 18' ' ' ARG . . . -165.47 106.94 0.28 Allowed Glycine 0 C--N 1.297 -1.605 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.555 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.869 0 C-N-CA 118.173 -1.411 . . . . 0.0 111.387 -179.257 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.1 ttm180 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.172 0.511 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -128.01 4.87 6.9 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.442 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 161.97 131.65 1.24 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.645 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.88 104.89 7.64 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.807 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.2 111.07 19.66 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-O 121.851 0.834 . . . . 0.0 108.847 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.37 120.6 8.92 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-O 122.059 0.933 . . . . 0.0 110.181 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.34 160.62 11.51 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 t -149.76 118.35 6.55 Favored 'General case' 0 C--N 1.267 -3.003 0 CA-C-O 122.529 1.157 . . . . 0.0 111.576 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.554 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.79 29.69 Favored Pre-proline 0 C--N 1.292 -1.929 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.354 -179.296 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.01 -13.28 4.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 122.884 0.939 . . . . 0.0 110.575 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.44 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.2 OUTLIER -85.05 -27.92 26.02 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.114 0.959 . . . . 0.0 109.33 177.529 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.554 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.26 40.7 p90 -173.08 159.67 3.98 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.769 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.717 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.3 OUTLIER -171.37 132.01 0.77 Allowed 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 116.655 -2.018 . . . . 0.0 110.51 178.589 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.717 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.97 156.02 2.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.777 0.799 . . . . 0.0 110.271 -179.357 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -131.58 128.63 39.6 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.643 -0.661 . . . . 0.0 110.08 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.719 HG22 ' NH1' ' A' ' 18' ' ' ARG . 0.4 OUTLIER -165.57 131.8 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.483 -0.76 . . . . 0.0 109.432 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -172.7 109.32 0.3 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.719 ' NH1' HG22 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.763 0 C-N-CA 117.886 -1.525 . . . . 0.0 111.841 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.043 0.449 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.36 -30.79 2.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.443 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.4 115.09 0.72 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.642 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.21 104.76 7.72 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.727 -1.189 . . . . 0.0 108.154 178.138 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.83 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -116.17 110.85 19.38 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.58 120.38 9.27 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-O 122.02 0.914 . . . . 0.0 110.298 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.01 160.05 11.74 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.8 t -148.43 118.56 7.25 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-O 122.514 1.149 . . . . 0.0 111.565 -179.337 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.11 136.7 29.43 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.417 -179.309 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.72 -14.67 8.02 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 122.791 0.89 . . . . 0.0 110.105 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.576 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 28.7 mmm-85 -84.71 -26.46 27.67 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 122.099 0.952 . . . . 0.0 109.524 177.501 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.576 ' CD2' ' HB2' ' A' ' 11' ' ' ARG 0.253 41.6 p90 -173.63 158.89 3.46 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -179.276 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.746 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.3 OUTLIER -171.34 130.98 0.74 Allowed 'General case' 0 C--N 1.289 -2.061 0 C-N-CA 116.554 -2.058 . . . . 0.0 110.595 178.789 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.746 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.6 t -163.11 156.43 2.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-O 121.746 0.784 . . . . 0.0 110.29 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.453 ' C ' ' CG2' ' A' ' 16' ' ' VAL . 0.3 OUTLIER -131.73 118.99 20.71 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.456 0.646 . . . . 0.0 109.969 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.453 ' CG2' ' C ' ' A' ' 15' ' ' CYS . 0.3 OUTLIER -153.69 121.92 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.473 -0.767 . . . . 0.0 109.326 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.56 105.21 0.24 Allowed Glycine 0 C--N 1.298 -1.573 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.166 -1.414 . . . . 0.0 111.224 -178.888 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ARG . . . . . 0.471 ' CB ' ' HD2' ' A' ' 4' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.198 0.523 . . . . 0.0 110.352 . . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.13 -61.53 1.26 Allowed Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.221 -1.552 . . . . 0.0 109.221 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.13 119.87 1.0 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.57 ' HA ' ' HA3' ' A' ' 17' ' ' GLY . 0.0 OUTLIER -145.5 104.68 3.93 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.596 -1.242 . . . . 0.0 109.283 177.798 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.782 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.7 mm? -115.68 112.05 21.5 Favored 'General case' 0 C--N 1.291 -1.959 0 C-N-CA 119.612 -0.835 . . . . 0.0 108.867 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.72 119.62 8.16 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 122.07 0.938 . . . . 0.0 110.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.84 160.65 10.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.0 t -148.03 118.02 7.21 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 122.641 1.21 . . . . 0.0 111.401 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.19 136.86 29.82 Favored Pre-proline 0 C--N 1.293 -1.859 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.319 -179.169 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -17.2 9.36 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 122.747 0.867 . . . . 0.0 110.133 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.584 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.9 mmt85 -80.96 -28.1 35.76 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.981 0.896 . . . . 0.0 109.534 177.541 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.584 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.254 42.1 p90 -173.62 159.88 3.65 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.049 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.79 130.99 0.83 Allowed 'General case' 0 C--N 1.288 -2.067 0 C-N-CA 116.698 -2.001 . . . . 0.0 110.564 178.617 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.1 156.16 2.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 CA-C-O 121.663 0.744 . . . . 0.0 110.087 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.36 119.69 21.05 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.524 0.678 . . . . 0.0 110.308 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.506 HG23 ' C ' ' A' ' 15' ' ' CYS . 69.3 t -156.09 123.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.57 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -167.75 105.27 0.23 Allowed Glycine 0 C--N 1.299 -1.502 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.425 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.847 0 C-N-CA 118.404 -1.318 . . . . 0.0 111.112 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.123 0.487 . . . . 0.0 110.147 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.98 -27.3 5.18 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.402 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 170.32 135.42 1.91 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.64 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -125.85 105.21 8.78 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.811 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -114.42 111.04 20.81 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-O 121.859 0.837 . . . . 0.0 108.842 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -151.65 121.43 7.02 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.078 0.942 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -167.92 160.76 12.5 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 -178.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -144.3 118.81 9.7 Favored 'General case' 0 C--N 1.265 -3.067 0 CA-C-O 122.529 1.157 . . . . 0.0 111.429 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.558 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.99 136.71 29.6 Favored Pre-proline 0 C--N 1.292 -1.899 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.203 -179.135 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -54.03 -16.08 8.62 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 122.772 0.88 . . . . 0.0 110.104 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.475 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 66.9 mtp180 -82.36 -28.4 31.55 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 122.103 0.954 . . . . 0.0 109.54 177.414 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.558 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 40.0 p90 -173.11 160.07 4.05 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 -178.594 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.752 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.14 128.13 0.87 Allowed 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 116.679 -2.009 . . . . 0.0 110.338 178.517 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -162.87 156.92 2.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 121.646 0.736 . . . . 0.0 110.574 -179.143 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.51 ' C ' HG23 ' A' ' 16' ' ' VAL . 16.5 t -126.68 132.31 51.21 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.572 0.701 . . . . 0.0 110.128 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.51 HG23 ' C ' ' A' ' 15' ' ' CYS . 92.3 t -156.15 131.94 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -164.35 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.453 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.834 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.393 -179.106 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.197 0.522 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -94.77 -33.3 6.76 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 166.59 127.86 0.93 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.654 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -130.29 104.52 7.33 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 177.522 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.814 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.95 110.93 18.31 Favored 'General case' 0 C--N 1.29 -2.003 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.1 t -153.5 122.03 6.29 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.435 1.112 . . . . 0.0 110.585 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.31 161.0 11.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.8 t -143.32 119.14 10.55 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-O 122.598 1.19 . . . . 0.0 111.757 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.562 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.05 136.31 28.99 Favored Pre-proline 0 C--N 1.292 -1.935 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.056 -179.341 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.95 -15.79 7.91 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 122.765 0.876 . . . . 0.0 110.142 -179.297 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.602 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 20.5 mmt85 -82.68 -27.31 31.36 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.978 0.894 . . . . 0.0 109.525 177.545 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.602 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 43.1 p90 -173.83 159.88 3.51 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -179.093 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.772 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.6 OUTLIER -170.14 127.68 0.85 Allowed 'General case' 0 C--N 1.289 -2.041 0 C-N-CA 116.642 -2.023 . . . . 0.0 110.569 178.593 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.27 155.85 2.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-O 121.465 0.65 . . . . 0.0 110.116 -179.19 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.495 ' C ' HG23 ' A' ' 16' ' ' VAL . 23.7 m -135.86 119.24 16.81 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.563 -0.711 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.495 HG23 ' C ' ' A' ' 15' ' ' CYS . 95.8 t -152.17 124.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 CA-C-O 121.65 0.738 . . . . 0.0 109.083 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.477 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.24 107.88 0.31 Allowed Glycine 0 C--N 1.295 -1.702 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.449 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.922 0 C-N-CA 118.392 -1.323 . . . . 0.0 111.664 -178.951 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.114 0.483 . . . . 0.0 110.198 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -61.94 -51.24 58.43 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -179.35 130.36 1.51 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ARG . . . . . 0.649 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.39 105.23 8.18 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.673 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LEU . . . . . 0.82 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.43 112.08 21.76 Favored 'General case' 0 C--N 1.291 -1.975 0 CA-C-O 121.922 0.868 . . . . 0.0 108.797 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 t -147.82 121.59 9.28 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 122.042 0.925 . . . . 0.0 110.221 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.42 160.16 13.02 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -178.633 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -149.77 118.87 6.73 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.554 1.168 . . . . 0.0 111.607 -179.252 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.16 136.54 29.32 Favored Pre-proline 0 C--N 1.293 -1.886 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.246 -179.377 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -16.68 8.45 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 122.726 0.856 . . . . 0.0 110.311 -179.263 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 27.0 mtp180 -81.28 -28.44 34.69 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 122.143 0.973 . . . . 0.0 109.54 177.522 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' PHE . . . . . 0.577 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.1 p90 -173.19 159.5 3.87 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 13' ' ' CYS . . . . . 0.747 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.2 OUTLIER -170.56 131.05 0.89 Allowed 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 116.577 -2.049 . . . . 0.0 110.571 178.657 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.92 156.47 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.711 0.767 . . . . 0.0 110.163 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' C ' HG23 ' A' ' 16' ' ' VAL . 48.9 t -133.48 131.2 39.59 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 121.592 0.71 . . . . 0.0 110.347 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 16' ' ' VAL . . . . . 0.504 HG23 ' C ' ' A' ' 15' ' ' CYS . 70.8 t -156.6 128.55 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.23 106.23 0.26 Allowed Glycine 0 C--N 1.295 -1.715 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ARG . . . . . 0.524 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.418 -1.313 . . . . 0.0 111.251 -179.28 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 9.1 tpp180 . . . . . 0 N--CA 1.492 1.634 0 CA-C-O 121.209 0.528 . . . . 0.0 110.153 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -74.35 -45.44 24.31 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.614 -1.395 . . . . 0.0 109.614 -179.935 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.425 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 175.27 131.27 1.41 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.973 -1.251 . . . . 0.0 109.973 -179.931 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.641 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.67 105.64 8.6 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.525 -1.287 . . . . 0.0 107.525 177.816 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.25 111.4 20.89 Favored 'General case' 0 C--N 1.289 -2.029 0 CA-C-O 121.867 0.841 . . . . 0.0 109.211 -179.42 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -147.98 119.97 8.22 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.022 0.915 . . . . 0.0 110.234 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.55 160.94 11.3 Favored 'General case' 0 C--N 1.295 -1.786 0 N-CA-C 108.087 -1.079 . . . . 0.0 108.087 -178.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.6 t -147.17 119.13 8.16 Favored 'General case' 0 C--N 1.269 -2.927 0 CA-C-O 122.536 1.16 . . . . 0.0 111.449 -179.581 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.572 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.51 136.69 29.5 Favored Pre-proline 0 C--N 1.293 -1.852 0 CA-C-N 114.968 -1.015 . . . . 0.0 109.415 -179.194 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.54 -14.1 6.65 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 O-C-N 122.885 0.94 . . . . 0.0 110.363 -179.38 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.464 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -84.51 -27.85 27.13 Favored 'General case' 0 N--CA 1.492 1.65 0 CA-C-O 122.171 0.986 . . . . 0.0 109.371 177.488 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.572 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 40.8 p90 -172.95 159.43 4.04 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 -178.733 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.713 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.4 OUTLIER -170.67 131.46 0.88 Allowed 'General case' 0 C--N 1.288 -2.087 0 C-N-CA 116.565 -2.054 . . . . 0.0 110.453 178.641 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.75 155.9 2.48 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 CA-C-O 121.631 0.729 . . . . 0.0 110.128 -179.403 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.527 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.0 OUTLIER -129.35 128.51 43.24 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 121.366 0.603 . . . . 0.0 110.141 -179.88 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.809 HG12 ' NH2' ' A' ' 18' ' ' ARG . 0.0 OUTLIER -165.02 136.77 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 CA-C-O 122.019 0.914 . . . . 0.0 109.692 179.774 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.07 107.19 0.28 Allowed Glycine 0 C--N 1.292 -1.914 0 N-CA-C 107.888 -2.085 . . . . 0.0 107.888 -179.987 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.809 ' NH2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.157 -1.417 . . . . 0.0 111.327 -179.039 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.7 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.102 0.477 . . . . 0.0 110.145 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -108.67 -29.24 4.22 Favored Glycine 0 N--CA 1.491 2.346 0 N-CA-C 109.677 -1.369 . . . . 0.0 109.677 -179.904 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -163.7 122.32 1.08 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.846 -1.302 . . . . 0.0 109.846 -179.966 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.647 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.59 104.86 7.69 Favored 'General case' 0 C--N 1.3 -1.582 0 C-N-CA 118.793 -1.163 . . . . 0.0 107.885 177.903 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.811 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.93 111.17 20.02 Favored 'General case' 0 C--N 1.29 -2.014 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.2 OUTLIER -147.09 120.89 9.25 Favored 'General case' 0 C--N 1.291 -1.953 0 CA-C-O 122.084 0.945 . . . . 0.0 110.259 -179.608 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.02 160.33 11.94 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 108.003 -1.11 . . . . 0.0 108.003 -178.684 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.8 t -149.64 117.99 6.46 Favored 'General case' 0 C--N 1.267 -2.987 0 CA-C-O 122.619 1.2 . . . . 0.0 111.552 -179.449 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.83 136.88 29.84 Favored Pre-proline 0 C--N 1.293 -1.885 0 CA-C-N 114.874 -1.057 . . . . 0.0 109.126 -179.322 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.83 -15.58 7.23 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 O-C-N 122.792 0.891 . . . . 0.0 110.336 -179.244 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.487 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 51.8 mtp180 -82.38 -28.36 31.54 Favored 'General case' 0 N--CA 1.491 1.575 0 CA-C-O 122.131 0.967 . . . . 0.0 109.511 177.496 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.566 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.0 p90 -173.15 159.77 3.96 Favored 'General case' 0 C--N 1.294 -1.805 0 N-CA-C 106.366 -1.716 . . . . 0.0 106.366 -178.766 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.713 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.2 OUTLIER -171.29 131.85 0.78 Allowed 'General case' 0 C--N 1.289 -2.055 0 C-N-CA 116.634 -2.026 . . . . 0.0 110.389 178.534 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.713 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.95 156.65 2.17 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.496 0 CA-C-O 121.703 0.763 . . . . 0.0 110.243 -179.315 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.498 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -131.48 123.28 27.74 Favored 'General case' 0 N--CA 1.492 1.659 0 CA-C-O 121.454 0.645 . . . . 0.0 110.215 -179.996 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG13 ' NH1' ' A' ' 18' ' ' ARG . 85.0 t -153.66 123.64 0.81 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.57 0 N-CA-C 109.132 -0.692 . . . . 0.0 109.132 179.666 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.433 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.85 105.21 0.23 Allowed Glycine 0 C--N 1.297 -1.629 0 N-CA-C 108.37 -1.892 . . . . 0.0 108.37 179.868 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.532 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.789 0 C-N-CA 118.454 -1.298 . . . . 0.0 111.086 -179.477 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . 0.495 ' HB3' ' HD3' ' A' ' 4' ' ' ARG . 8.3 tpp180 . . . . . 0 N--CA 1.492 1.664 0 CA-C-O 121.234 0.54 . . . . 0.0 110.165 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -68.35 -35.76 82.94 Favored Glycine 0 N--CA 1.492 2.368 0 N-CA-C 109.307 -1.517 . . . . 0.0 109.307 179.938 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.1 121.97 1.23 Allowed Glycine 0 N--CA 1.487 2.073 0 N-CA-C 109.086 -1.605 . . . . 0.0 109.086 179.684 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.564 ' CD ' ' N ' ' A' ' 4' ' ' ARG . 0.0 OUTLIER -142.15 106.95 4.88 Favored 'General case' 0 C--N 1.294 -1.819 0 C-N-CA 118.729 -1.188 . . . . 0.0 109.373 177.815 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.785 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.8 mm? -112.94 113.14 25.07 Favored 'General case' 0 C--N 1.29 -2.019 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 179.22 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.87 120.91 9.4 Favored 'General case' 0 C--N 1.29 -1.98 0 CA-C-O 121.961 0.886 . . . . 0.0 110.237 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.0 160.27 11.93 Favored 'General case' 0 C--N 1.296 -1.744 0 N-CA-C 108.007 -1.108 . . . . 0.0 108.007 -178.675 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.9 t -148.34 118.59 7.3 Favored 'General case' 0 C--N 1.266 -3.023 0 CA-C-O 122.507 1.146 . . . . 0.0 111.626 -179.255 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.567 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.7 136.39 28.68 Favored Pre-proline 0 C--N 1.292 -1.92 0 CA-C-N 114.91 -1.041 . . . . 0.0 109.388 -179.37 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.46 -14.24 6.7 Favored 'Trans proline' 0 C--N 1.306 -1.675 0 O-C-N 122.78 0.884 . . . . 0.0 110.259 -179.46 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.556 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 20.1 mmm-85 -85.12 -26.99 26.54 Favored 'General case' 0 N--CA 1.492 1.629 0 CA-C-O 121.983 0.897 . . . . 0.0 109.55 177.529 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.567 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.252 40.4 p90 -173.43 159.69 3.75 Favored 'General case' 0 C--N 1.294 -1.819 0 N-CA-C 106.227 -1.768 . . . . 0.0 106.227 -178.99 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.737 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.88 132.55 0.88 Allowed 'General case' 0 C--N 1.288 -2.079 0 C-N-CA 116.586 -2.045 . . . . 0.0 110.336 178.803 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.737 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -163.08 156.67 2.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.537 0 CA-C-O 121.736 0.779 . . . . 0.0 110.361 -179.191 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.499 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -130.98 123.9 29.82 Favored 'General case' 0 N--CA 1.491 1.607 0 CA-C-O 121.419 0.628 . . . . 0.0 110.161 179.93 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.499 HG23 ' C ' ' A' ' 15' ' ' CYS . 86.5 t -154.23 126.39 1.02 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 CA-C-O 121.622 0.725 . . . . 0.0 109.155 179.689 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.503 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.5 105.57 0.25 Allowed Glycine 0 C--N 1.295 -1.726 0 N-CA-C 108.314 -1.915 . . . . 0.0 108.314 -179.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.446 ' N ' ' HD3' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.872 0 C-N-CA 118.516 -1.274 . . . . 0.0 111.379 -179.326 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.493 1.678 0 CA-C-O 121.177 0.513 . . . . 0.0 110.241 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -105.99 -23.86 7.2 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.687 -1.365 . . . . 0.0 109.687 -179.961 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.42 ' N ' ' HD3' ' A' ' 4' ' ' ARG . . . -131.6 106.46 0.67 Allowed Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.896 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.639 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.5 104.74 7.86 Favored 'General case' 0 C--N 1.299 -1.617 0 C-N-CA 118.728 -1.189 . . . . 0.0 107.876 177.763 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.814 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.98 109.94 17.64 Favored 'General case' 0 C--N 1.291 -1.941 0 CA-C-O 121.813 0.816 . . . . 0.0 108.808 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.449 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 53.7 t -156.57 120.5 4.35 Favored 'General case' 0 C--N 1.291 -1.956 0 CA-C-O 122.389 1.09 . . . . 0.0 110.474 179.88 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -169.35 161.03 9.78 Favored 'General case' 0 C--N 1.293 -1.867 0 N-CA-C 107.484 -1.302 . . . . 0.0 107.484 -178.473 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.423 ' HA ' ' CB ' ' A' ' 13' ' ' CYS . 4.8 t -142.12 118.97 11.17 Favored 'General case' 0 C--N 1.267 -3.0 0 CA-C-O 122.414 1.102 . . . . 0.0 111.148 -179.725 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.547 ' HG3' ' CZ ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -137.81 137.97 22.81 Favored Pre-proline 0 C--N 1.29 -1.985 0 N-CA-C 107.981 -1.118 . . . . 0.0 107.981 -179.41 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 28.2 Cg_endo -50.77 -17.8 3.52 Favored 'Trans proline' 0 C--N 1.306 -1.663 0 O-C-N 122.727 0.856 . . . . 0.0 110.801 -178.284 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.531 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 17.2 mmm-85 -73.85 -34.54 64.55 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 122.122 0.963 . . . . 0.0 109.118 177.141 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.547 ' CZ ' ' HG3' ' A' ' 9' ' ' ARG 0.255 40.7 p90 -174.09 162.33 3.76 Favored 'General case' 0 C--N 1.295 -1.773 0 N-CA-C 106.762 -1.57 . . . . 0.0 106.762 -178.788 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.756 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.6 OUTLIER -168.47 125.48 1.04 Allowed 'General case' 0 C--N 1.29 -2.01 0 C-N-CA 116.868 -1.933 . . . . 0.0 110.585 178.351 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.756 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.43 156.71 2.01 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.539 0 O-C-N 121.704 -0.623 . . . . 0.0 109.877 -179.109 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' C ' HG23 ' A' ' 16' ' ' VAL . 35.9 m -135.68 118.07 15.72 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.494 -0.754 . . . . 0.0 110.878 179.951 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.506 HG23 ' C ' ' A' ' 15' ' ' CYS . 75.4 t -155.51 123.51 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 179.325 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.46 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.6 107.17 0.29 Allowed Glycine 0 C--N 1.298 -1.548 0 N-CA-C 108.21 -1.956 . . . . 0.0 108.21 -179.762 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.447 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.902 0 C-N-CA 118.49 -1.284 . . . . 0.0 111.373 -179.198 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.263 0.554 . . . . 0.0 110.182 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -72.62 -27.15 69.89 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.467 -1.453 . . . . 0.0 109.467 179.915 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.453 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 149.02 126.86 1.54 Allowed Glycine 0 N--CA 1.49 2.275 0 N-CA-C 109.869 -1.293 . . . . 0.0 109.869 -179.888 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.644 ' HA ' ' HA3' ' A' ' 17' ' ' GLY . 0.0 OUTLIER -131.57 103.96 6.69 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 107.749 -1.204 . . . . 0.0 107.749 177.694 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.813 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.99 111.38 18.87 Favored 'General case' 0 C--N 1.29 -1.99 0 N-CA-C 108.592 -0.892 . . . . 0.0 108.592 179.851 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.47 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 48.7 t -152.84 123.12 7.12 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.37 1.081 . . . . 0.0 110.598 -179.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.42 161.02 11.63 Favored 'General case' 0 C--N 1.294 -1.827 0 N-CA-C 107.379 -1.341 . . . . 0.0 107.379 -178.753 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.1 t -145.08 118.82 9.21 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-O 122.521 1.153 . . . . 0.0 111.779 -179.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.551 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.53 136.18 28.56 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.846 -1.07 . . . . 0.0 109.181 -179.438 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.45 -13.2 5.04 Favored 'Trans proline' 0 C--N 1.305 -1.714 0 O-C-N 122.791 0.89 . . . . 0.0 110.359 -179.463 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.557 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 8.1 mmm-85 -85.67 -27.11 25.58 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.134 0.968 . . . . 0.0 109.577 177.525 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.557 ' CD2' ' HB2' ' A' ' 11' ' ' ARG 0.253 40.1 p90 -173.53 159.81 3.71 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.3 -1.741 . . . . 0.0 106.3 -179.077 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.774 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.87 129.32 0.78 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.624 -2.03 . . . . 0.0 110.5 178.767 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.774 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.44 155.41 2.35 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 CA-C-O 121.46 0.648 . . . . 0.0 109.981 -179.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.495 ' C ' HG23 ' A' ' 16' ' ' VAL . 18.6 m -137.2 117.72 13.83 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.635 -0.665 . . . . 0.0 110.523 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.495 HG23 ' C ' ' A' ' 15' ' ' CYS . 96.0 t -153.02 121.2 0.7 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 N-CA-C 108.994 -0.743 . . . . 0.0 108.994 179.564 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.644 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -168.16 106.56 0.26 Allowed Glycine 0 C--N 1.297 -1.603 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.433 ' NH2' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.339 -1.344 . . . . 0.0 111.126 -179.384 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.665 0 CA-C-O 121.224 0.535 . . . . 0.0 110.166 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -81.35 -11.1 83.77 Favored Glycine 0 N--CA 1.491 2.337 0 N-CA-C 109.897 -1.281 . . . . 0.0 109.897 179.861 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.409 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -158.52 120.43 0.97 Allowed Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.767 -1.333 . . . . 0.0 109.767 -179.972 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.646 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.25 105.55 8.62 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.648 -1.241 . . . . 0.0 107.648 177.76 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.812 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.4 110.95 20.09 Favored 'General case' 0 C--N 1.291 -1.963 0 CA-C-O 121.879 0.847 . . . . 0.0 109.066 -179.634 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -148.31 120.71 8.46 Favored 'General case' 0 C--N 1.291 -1.938 0 CA-C-O 122.181 0.991 . . . . 0.0 110.092 -179.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.25 159.83 11.08 Favored 'General case' 0 C--N 1.294 -1.829 0 N-CA-C 107.757 -1.201 . . . . 0.0 107.757 -178.611 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -149.65 119.35 7.02 Favored 'General case' 0 C--N 1.268 -2.958 0 CA-C-O 122.598 1.189 . . . . 0.0 111.379 -179.397 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.565 ' HB2' ' CE1' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.7 136.6 29.22 Favored Pre-proline 0 C--N 1.292 -1.907 0 CA-C-N 114.953 -1.022 . . . . 0.0 109.28 -179.242 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.9 Cg_endo -54.52 -12.88 4.72 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.92 0.958 . . . . 0.0 110.634 -179.317 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.427 ' HB3' ' HD2' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -87.53 -25.91 23.43 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.234 -0.916 . . . . 0.0 109.406 177.667 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' CE1' ' HB2' ' A' ' 9' ' ' ARG 0.256 40.3 p90 -173.61 159.69 3.62 Favored 'General case' 0 C--N 1.296 -1.751 0 N-CA-C 106.542 -1.651 . . . . 0.0 106.542 -178.95 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.421 ' HB2' ' H ' ' A' ' 9' ' ' ARG . 0.6 OUTLIER -170.13 133.31 1.13 Allowed 'General case' 0 C--N 1.288 -2.107 0 C-N-CA 116.725 -1.99 . . . . 0.0 110.733 178.647 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -158.62 156.02 4.13 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 CA-C-O 121.766 0.793 . . . . 0.0 110.327 -179.756 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.534 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -136.62 126.58 25.93 Favored 'General case' 0 N--CA 1.494 1.76 0 CA-C-O 121.398 0.618 . . . . 0.0 110.273 179.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.534 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -165.3 138.19 0.95 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 CA-C-O 121.962 0.887 . . . . 0.0 109.649 179.676 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.0 105.62 0.25 Allowed Glycine 0 C--N 1.29 -2.006 0 N-CA-C 108.032 -2.027 . . . . 0.0 108.032 179.811 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.438 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.846 0 C-N-CA 118.471 -1.292 . . . . 0.0 111.359 -179.282 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 10.1 ptp180 . . . . . 0 N--CA 1.493 1.71 0 CA-C-O 121.043 0.449 . . . . 0.0 110.205 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 157.73 -29.83 0.49 Allowed Glycine 0 N--CA 1.492 2.379 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.976 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -155.79 118.67 0.86 Allowed Glycine 0 N--CA 1.491 2.304 0 N-CA-C 109.696 -1.362 . . . . 0.0 109.696 179.966 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.644 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.58 105.12 7.85 Favored 'General case' 0 C--N 1.299 -1.614 0 C-N-CA 118.765 -1.174 . . . . 0.0 107.919 177.945 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.81 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.61 111.38 20.58 Favored 'General case' 0 C--N 1.29 -1.996 0 CA-C-O 121.942 0.877 . . . . 0.0 108.664 -179.981 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.4 OUTLIER -146.93 120.55 9.15 Favored 'General case' 0 C--N 1.291 -1.959 0 CA-C-O 122.02 0.914 . . . . 0.0 110.245 -179.402 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.23 160.33 11.5 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.6 t -148.23 118.34 7.25 Favored 'General case' 0 C--N 1.266 -3.046 0 CA-C-O 122.574 1.178 . . . . 0.0 111.457 -179.415 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.561 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.59 136.9 29.83 Favored Pre-proline 0 C--N 1.292 -1.898 0 CA-C-N 114.821 -1.082 . . . . 0.0 109.301 -179.307 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.8 Cg_endo -54.04 -15.48 7.65 Favored 'Trans proline' 0 C--N 1.304 -1.779 0 O-C-N 122.785 0.887 . . . . 0.0 110.252 -179.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.495 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 63.3 mtp180 -82.91 -28.22 30.1 Favored 'General case' 0 N--CA 1.489 1.515 0 CA-C-O 122.148 0.975 . . . . 0.0 109.575 177.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.561 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.3 p90 -173.21 159.9 3.95 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.399 -1.704 . . . . 0.0 106.399 -178.769 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.729 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.91 131.25 0.82 Allowed 'General case' 0 C--N 1.289 -2.053 0 C-N-CA 116.677 -2.009 . . . . 0.0 110.457 178.592 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.729 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.1 156.82 2.07 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.484 0 CA-C-O 121.847 0.832 . . . . 0.0 110.324 -179.262 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.2 OUTLIER -130.9 122.83 27.69 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.671 -0.643 . . . . 0.0 110.072 -179.985 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.501 HG23 ' C ' ' A' ' 15' ' ' CYS . 99.3 t -153.8 123.59 0.79 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 CA-C-O 121.562 0.696 . . . . 0.0 109.386 179.717 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.448 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.2 106.18 0.26 Allowed Glycine 0 C--N 1.296 -1.648 0 N-CA-C 108.162 -1.975 . . . . 0.0 108.162 179.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.544 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.793 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.239 -179.36 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.6 ttm180 . . . . . 0 N--CA 1.492 1.633 0 CA-C-O 121.247 0.546 . . . . 0.0 110.111 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -127.09 -0.89 6.91 Favored Glycine 0 N--CA 1.493 2.486 0 N-CA-C 110.165 -1.174 . . . . 0.0 110.165 -179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.443 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 180.0 129.57 1.36 Allowed Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.526 -1.43 . . . . 0.0 109.526 -179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.64 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.98 104.87 7.84 Favored 'General case' 0 C--N 1.3 -1.578 0 C-N-CA 118.7 -1.2 . . . . 0.0 107.912 178.23 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.822 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.01 111.36 20.23 Favored 'General case' 0 C--N 1.289 -2.033 0 N-CA-C 108.48 -0.933 . . . . 0.0 108.48 179.901 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.1 t -150.22 122.2 8.22 Favored 'General case' 0 C--N 1.291 -1.974 0 CA-C-O 122.154 0.978 . . . . 0.0 110.274 -179.449 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.79 160.33 12.41 Favored 'General case' 0 C--N 1.295 -1.785 0 N-CA-C 108.039 -1.097 . . . . 0.0 108.039 -178.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.5 t -147.4 118.64 7.8 Favored 'General case' 0 C--N 1.266 -3.027 0 CA-C-O 122.463 1.125 . . . . 0.0 111.462 -179.26 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.566 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -127.26 136.54 29.04 Favored Pre-proline 0 C--N 1.29 -1.987 0 CA-C-N 114.95 -1.023 . . . . 0.0 109.263 -179.102 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -54.4 -14.83 7.49 Favored 'Trans proline' 0 C--N 1.305 -1.73 0 O-C-N 122.84 0.916 . . . . 0.0 110.227 -179.357 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.572 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.3 mmm180 -84.79 -26.47 27.5 Favored 'General case' 0 N--CA 1.49 1.525 0 CA-C-O 122.021 0.915 . . . . 0.0 109.587 177.621 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.572 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 42.0 p90 -173.74 160.09 3.62 Favored 'General case' 0 C--N 1.295 -1.772 0 N-CA-C 106.385 -1.709 . . . . 0.0 106.385 -179.027 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.6 131.02 0.88 Allowed 'General case' 0 C--N 1.288 -2.072 0 C-N-CA 116.609 -2.036 . . . . 0.0 110.53 178.67 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.47 156.72 2.0 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 CA-C-O 121.666 0.746 . . . . 0.0 110.28 -179.171 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.517 ' O ' HG23 ' A' ' 16' ' ' VAL . 38.7 t -133.07 131.36 40.51 Favored 'General case' 0 N--CA 1.492 1.642 0 CA-C-O 121.616 0.722 . . . . 0.0 110.304 179.745 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 15' ' ' CYS . 76.1 t -157.01 128.28 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.53 0 CA-C-O 121.644 0.735 . . . . 0.0 109.049 179.737 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.34 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.752 0 N-CA-C 108.121 -1.991 . . . . 0.0 108.121 179.926 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.451 ' NH2' HG12 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.828 0 C-N-CA 118.443 -1.303 . . . . 0.0 111.383 -179.306 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 1.7 tpp85 . . . . . 0 N--CA 1.492 1.658 0 CA-C-O 121.185 0.517 . . . . 0.0 110.202 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -111.22 -11.86 17.03 Favored Glycine 0 N--CA 1.494 2.503 0 N-CA-C 109.907 -1.277 . . . . 0.0 109.907 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.433 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.18 114.78 0.71 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.652 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.82 104.67 7.53 Favored 'General case' 0 C--N 1.3 -1.555 0 C-N-CA 118.679 -1.209 . . . . 0.0 107.95 177.9 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.823 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.64 110.57 18.68 Favored 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 108.519 -0.919 . . . . 0.0 108.519 179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.447 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.5 t -154.99 122.33 5.6 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-O 122.343 1.068 . . . . 0.0 110.657 -179.763 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.56 161.03 11.34 Favored 'General case' 0 C--N 1.293 -1.856 0 N-CA-C 107.278 -1.379 . . . . 0.0 107.278 -178.661 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 5.5 t -142.24 119.06 11.16 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.542 1.163 . . . . 0.0 111.687 -179.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.545 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.89 136.62 29.45 Favored Pre-proline 0 C--N 1.292 -1.915 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.138 -179.272 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -54.04 -14.91 6.71 Favored 'Trans proline' 0 C--N 1.307 -1.645 0 O-C-N 122.767 0.877 . . . . 0.0 110.204 -179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.542 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 8.8 mmm-85 -83.88 -27.69 28.47 Favored 'General case' 0 N--CA 1.49 1.562 0 CA-C-O 121.996 0.903 . . . . 0.0 109.594 177.488 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.545 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 42.3 p90 -173.62 160.55 3.79 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.696 -1.594 . . . . 0.0 106.696 -178.864 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.761 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.7 OUTLIER -170.32 127.36 0.81 Allowed 'General case' 0 C--N 1.288 -2.075 0 C-N-CA 116.815 -1.954 . . . . 0.0 110.487 178.482 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.761 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.0 t -163.31 156.11 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.592 -0.693 . . . . 0.0 110.111 -179.127 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.48 ' C ' HG23 ' A' ' 16' ' ' VAL . 36.8 m -136.26 119.21 16.34 Favored 'General case' 0 N--CA 1.493 1.715 0 O-C-N 121.618 -0.676 . . . . 0.0 110.494 179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.48 HG23 ' C ' ' A' ' 15' ' ' CYS . 94.5 t -153.1 123.68 0.87 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.58 -0.7 . . . . 0.0 109.231 179.654 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.419 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.08 108.78 0.34 Allowed Glycine 0 C--N 1.296 -1.668 0 N-CA-C 107.977 -2.049 . . . . 0.0 107.977 -179.823 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.849 0 C-N-CA 118.04 -1.464 . . . . 0.0 111.345 -178.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 3.3 tpp85 . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.21 0.529 . . . . 0.0 110.189 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -77.07 -21.17 74.43 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.833 -1.307 . . . . 0.0 109.833 179.988 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.441 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 179.0 130.48 1.44 Allowed Glycine 0 N--CA 1.491 2.301 0 N-CA-C 109.92 -1.272 . . . . 0.0 109.92 -179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.648 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.55 105.23 7.93 Favored 'General case' 0 C--N 1.298 -1.652 0 N-CA-C 107.504 -1.295 . . . . 0.0 107.504 177.657 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.816 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.62 111.28 19.65 Favored 'General case' 0 C--N 1.289 -2.034 0 CA-C-O 121.758 0.79 . . . . 0.0 108.913 -179.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 5.0 t -150.19 121.06 7.61 Favored 'General case' 0 C--N 1.29 -2.008 0 CA-C-O 122.11 0.957 . . . . 0.0 110.511 -179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.75 160.95 10.88 Favored 'General case' 0 C--N 1.295 -1.765 0 N-CA-C 107.829 -1.175 . . . . 0.0 107.829 -178.642 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -145.08 118.32 8.94 Favored 'General case' 0 C--N 1.266 -3.052 0 CA-C-O 122.514 1.149 . . . . 0.0 111.523 -179.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.09 136.94 29.95 Favored Pre-proline 0 C--N 1.293 -1.882 0 CA-C-N 114.89 -1.05 . . . . 0.0 109.269 -179.295 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -53.98 -16.8 9.67 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 O-C-N 122.811 0.9 . . . . 0.0 110.109 -179.289 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.562 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 17.8 mmm-85 -81.12 -28.2 35.24 Favored 'General case' 0 N--CA 1.49 1.548 0 CA-C-O 122.023 0.916 . . . . 0.0 109.378 177.45 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.569 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.255 39.6 p90 -173.72 159.94 3.6 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 106.55 -1.648 . . . . 0.0 106.55 -178.964 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.767 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.1 128.79 0.89 Allowed 'General case' 0 C--N 1.289 -2.047 0 C-N-CA 116.621 -2.032 . . . . 0.0 110.429 178.585 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.767 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -163.35 156.85 2.0 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 CA-C-O 121.639 0.733 . . . . 0.0 110.276 -179.167 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.581 ' O ' HG23 ' A' ' 16' ' ' VAL . 24.8 t -129.52 129.67 44.8 Favored 'General case' 0 N--CA 1.492 1.638 0 CA-C-O 121.657 0.741 . . . . 0.0 110.387 179.526 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.581 HG23 ' O ' ' A' ' 15' ' ' CYS . 55.4 t -157.72 124.3 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 N-CA-C 109.033 -0.729 . . . . 0.0 109.033 179.861 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.455 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -167.24 105.5 0.24 Allowed Glycine 0 C--N 1.298 -1.567 0 N-CA-C 108.434 -1.866 . . . . 0.0 108.434 179.84 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.48 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.825 0 C-N-CA 118.431 -1.307 . . . . 0.0 111.235 -179.441 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.492 1.663 0 CA-C-O 121.24 0.543 . . . . 0.0 110.203 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -70.1 -17.7 74.07 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.405 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 168.69 134.2 1.69 Allowed Glycine 0 N--CA 1.491 2.334 0 N-CA-C 109.905 -1.278 . . . . 0.0 109.905 -179.872 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.656 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.8 105.42 8.43 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 107.747 -1.205 . . . . 0.0 107.747 177.718 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -115.04 110.87 20.23 Favored 'General case' 0 C--N 1.289 -2.03 0 CA-C-O 121.879 0.847 . . . . 0.0 108.798 -179.67 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.5 OUTLIER -148.86 121.21 8.43 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.137 0.97 . . . . 0.0 110.356 -179.647 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.26 160.34 11.45 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 107.781 -1.192 . . . . 0.0 107.781 -178.787 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.4 t -149.72 118.79 6.73 Favored 'General case' 0 C--N 1.267 -2.98 0 CA-C-O 122.592 1.187 . . . . 0.0 111.632 -179.267 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.565 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.02 136.56 29.38 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.912 -1.04 . . . . 0.0 109.083 -179.422 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.41 -16.13 6.93 Favored 'Trans proline' 0 C--N 1.305 -1.718 0 O-C-N 122.783 0.886 . . . . 0.0 110.461 -179.134 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.481 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 73.6 mtp180 -81.74 -28.17 33.47 Favored 'General case' 0 N--CA 1.491 1.596 0 CA-C-O 122.011 0.91 . . . . 0.0 109.651 177.478 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.565 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 39.9 p90 -173.2 160.02 3.98 Favored 'General case' 0 C--N 1.294 -1.828 0 N-CA-C 106.544 -1.65 . . . . 0.0 106.544 -178.663 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.591 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -171.07 133.6 0.89 Allowed 'General case' 0 C--N 1.286 -2.155 0 C-N-CA 116.741 -1.984 . . . . 0.0 110.464 178.609 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.591 HG23 ' O ' ' A' ' 13' ' ' CYS . 0.9 OUTLIER -162.1 156.02 2.71 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.557 0 CA-C-O 121.627 0.727 . . . . 0.0 110.158 -179.338 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.9 129.37 38.27 Favored 'General case' 0 N--CA 1.493 1.704 0 CA-C-O 121.465 0.65 . . . . 0.0 110.323 -179.846 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -163.99 133.82 0.75 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 CA-C-O 121.981 0.896 . . . . 0.0 109.493 179.59 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -168.14 107.16 0.27 Allowed Glycine 0 C--N 1.293 -1.82 0 N-CA-C 108.083 -2.007 . . . . 0.0 108.083 -179.755 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.475 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.146 -1.422 . . . . 0.0 111.486 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 12.6 ptp180 . . . . . 0 N--CA 1.493 1.714 0 CA-C-O 121.115 0.484 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 152.34 -24.28 0.87 Allowed Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.594 -1.402 . . . . 0.0 109.594 -179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.435 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -151.75 117.21 0.81 Allowed Glycine 0 N--CA 1.489 2.233 0 N-CA-C 109.57 -1.412 . . . . 0.0 109.57 179.953 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.639 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -127.54 106.08 8.93 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 107.489 -1.3 . . . . 0.0 107.489 177.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.825 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.18 111.61 21.26 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-O 121.981 0.896 . . . . 0.0 109.291 -179.369 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -147.25 119.59 8.39 Favored 'General case' 0 C--N 1.292 -1.917 0 CA-C-O 122.139 0.971 . . . . 0.0 110.081 179.936 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -169.52 161.61 9.71 Favored 'General case' 0 C--N 1.296 -1.757 0 N-CA-C 107.915 -1.143 . . . . 0.0 107.915 -178.305 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -144.2 117.69 9.13 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.545 1.164 . . . . 0.0 111.504 -179.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.587 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.73 29.61 Favored Pre-proline 0 C--N 1.292 -1.893 0 CA-C-N 114.863 -1.062 . . . . 0.0 109.192 -179.429 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -53.34 -17.96 9.91 Favored 'Trans proline' 0 C--N 1.306 -1.695 0 O-C-N 122.707 0.846 . . . . 0.0 110.194 -179.194 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.647 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmt180 -79.21 -28.64 42.58 Favored 'General case' 0 N--CA 1.491 1.577 0 CA-C-O 121.986 0.898 . . . . 0.0 109.439 177.523 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.647 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 42.3 p90 -173.51 159.82 3.72 Favored 'General case' 0 C--N 1.296 -1.752 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -179.146 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.726 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.76 128.8 0.78 Allowed 'General case' 0 C--N 1.289 -2.035 0 C-N-CA 116.486 -2.086 . . . . 0.0 110.484 178.513 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.726 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -162.3 155.77 2.71 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 CA-C-O 121.593 0.711 . . . . 0.0 110.027 -179.402 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.531 ' C ' HG22 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -125.01 129.37 50.18 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.656 -0.652 . . . . 0.0 110.06 179.97 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.531 HG22 ' C ' ' A' ' 15' ' ' CYS . 0.0 OUTLIER -165.12 136.28 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 CA-C-O 121.911 0.862 . . . . 0.0 109.64 179.773 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -166.09 105.55 0.24 Allowed Glycine 0 C--N 1.291 -1.943 0 N-CA-C 108.055 -2.018 . . . . 0.0 108.055 179.924 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.442 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.804 0 C-N-CA 118.567 -1.253 . . . . 0.0 111.393 -179.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 4.1 ttm180 . . . . . 0 N--CA 1.492 1.635 0 CA-C-O 121.259 0.552 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -103.74 -45.64 1.49 Allowed Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.616 -1.394 . . . . 0.0 109.616 179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.434 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -178.41 128.54 1.28 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.659 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.97 104.63 7.7 Favored 'General case' 0 C--N 1.301 -1.523 0 C-N-CA 118.788 -1.165 . . . . 0.0 107.975 177.855 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -116.75 110.43 18.41 Favored 'General case' 0 C--N 1.291 -1.969 0 CA-C-O 121.924 0.868 . . . . 0.0 108.844 179.958 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.45 119.64 8.31 Favored 'General case' 0 C--N 1.292 -1.909 0 CA-C-O 122.14 0.972 . . . . 0.0 110.242 -179.861 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.9 160.57 10.31 Favored 'General case' 0 C--N 1.296 -1.754 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.589 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . 0.4 ' HA ' ' CB ' ' A' ' 13' ' ' CYS . 7.8 t -149.66 117.29 6.18 Favored 'General case' 0 C--N 1.268 -2.952 0 CA-C-O 122.536 1.16 . . . . 0.0 111.578 -179.788 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.559 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -130.16 137.17 30.27 Favored Pre-proline 0 C--N 1.291 -1.938 0 CA-C-N 114.876 -1.057 . . . . 0.0 109.047 -179.483 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.3 Cg_endo -53.39 -16.57 7.53 Favored 'Trans proline' 0 C--N 1.306 -1.683 0 O-C-N 122.83 0.911 . . . . 0.0 110.251 -179.234 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.547 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 4.7 mmm180 -80.45 -28.77 37.6 Favored 'General case' 0 N--CA 1.489 1.487 0 CA-C-O 122.07 0.938 . . . . 0.0 109.49 177.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.559 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 41.5 p90 -173.41 159.86 3.8 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 106.449 -1.686 . . . . 0.0 106.449 -178.917 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.736 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -171.57 130.68 0.7 Allowed 'General case' 0 C--N 1.29 -1.985 0 C-N-CA 116.574 -2.05 . . . . 0.0 110.535 178.43 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.736 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.6 t -162.7 156.06 2.44 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 CA-C-O 121.656 0.741 . . . . 0.0 110.022 -179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.501 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.73 119.46 20.38 Favored 'General case' 0 N--CA 1.492 1.645 0 CA-C-O 121.495 0.664 . . . . 0.0 110.356 -179.905 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.532 HG13 HH11 ' A' ' 18' ' ' ARG . 91.4 t -154.41 121.98 0.64 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 CA-C-O 121.495 0.664 . . . . 0.0 109.224 179.503 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.483 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.73 107.66 0.3 Allowed Glycine 0 C--N 1.297 -1.627 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.532 HH11 HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.818 0 C-N-CA 118.111 -1.436 . . . . 0.0 111.307 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.115 0.483 . . . . 0.0 110.176 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -63.93 -33.23 86.68 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -179.878 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.439 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 169.25 134.21 1.7 Allowed Glycine 0 N--CA 1.491 2.308 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.643 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.97 105.07 7.96 Favored 'General case' 0 C--N 1.299 -1.608 0 N-CA-C 107.815 -1.18 . . . . 0.0 107.815 177.953 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.818 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -115.74 111.15 20.13 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 108.569 -0.9 . . . . 0.0 108.569 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -150.12 120.9 7.57 Favored 'General case' 0 C--N 1.29 -2.009 0 CA-C-O 122.093 0.949 . . . . 0.0 110.428 -179.638 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.37 160.74 11.55 Favored 'General case' 0 C--N 1.295 -1.788 0 N-CA-C 107.931 -1.137 . . . . 0.0 107.931 -178.6 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 7.2 t -145.26 118.74 9.06 Favored 'General case' 0 C--N 1.266 -3.033 0 CA-C-O 122.55 1.167 . . . . 0.0 111.41 -179.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.563 ' HB2' ' CE2' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -126.1 136.16 28.12 Favored Pre-proline 0 C--N 1.292 -1.932 0 CA-C-N 114.937 -1.029 . . . . 0.0 109.309 -179.265 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.2 Cg_endo -54.89 -13.18 5.77 Favored 'Trans proline' 0 C--N 1.305 -1.716 0 O-C-N 122.791 0.89 . . . . 0.0 110.324 -179.421 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.554 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 3.2 mmm-85 -86.99 -26.36 23.82 Favored 'General case' 0 N--CA 1.49 1.565 0 CA-C-O 122.046 0.927 . . . . 0.0 109.441 177.623 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.563 ' CE2' ' HB2' ' A' ' 9' ' ' ARG 0.253 41.5 p90 -173.58 159.8 3.67 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.257 -1.757 . . . . 0.0 106.257 -179.168 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.762 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.4 OUTLIER -170.62 130.93 0.87 Allowed 'General case' 0 C--N 1.287 -2.118 0 C-N-CA 116.686 -2.005 . . . . 0.0 110.356 178.842 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.7 t -163.54 156.92 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.464 0 CA-C-O 121.603 0.716 . . . . 0.0 110.342 -179.092 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.553 ' O ' HG23 ' A' ' 16' ' ' VAL . 36.6 t -131.76 129.62 40.82 Favored 'General case' 0 N--CA 1.492 1.673 0 CA-C-O 121.656 0.741 . . . . 0.0 110.471 179.803 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.555 HG13 ' NH1' ' A' ' 18' ' ' ARG . 72.9 t -157.78 126.34 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 CA-C-O 121.556 0.693 . . . . 0.0 109.146 179.736 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.406 ' H ' ' HE ' ' A' ' 18' ' ' ARG . . . -165.47 106.94 0.28 Allowed Glycine 0 C--N 1.297 -1.605 0 N-CA-C 108.168 -1.973 . . . . 0.0 108.168 179.991 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.555 ' NH1' HG13 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.869 0 C-N-CA 118.173 -1.411 . . . . 0.0 111.387 -179.257 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 5.1 ttm180 . . . . . 0 N--CA 1.491 1.618 0 CA-C-O 121.172 0.511 . . . . 0.0 110.167 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -128.01 4.87 6.9 Favored Glycine 0 N--CA 1.493 2.437 0 N-CA-C 110.037 -1.225 . . . . 0.0 110.037 179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.442 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 161.97 131.65 1.24 Allowed Glycine 0 N--CA 1.492 2.411 0 N-CA-C 109.866 -1.293 . . . . 0.0 109.866 -179.942 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.645 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.88 104.89 7.64 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.852 -1.166 . . . . 0.0 107.852 177.807 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.817 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.0 mm? -116.2 111.07 19.66 Favored 'General case' 0 C--N 1.29 -1.983 0 CA-C-O 121.851 0.834 . . . . 0.0 108.847 -179.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.37 120.6 8.92 Favored 'General case' 0 C--N 1.291 -1.962 0 CA-C-O 122.059 0.933 . . . . 0.0 110.181 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.34 160.62 11.51 Favored 'General case' 0 C--N 1.295 -1.768 0 N-CA-C 108.008 -1.108 . . . . 0.0 108.008 -178.673 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.1 t -149.76 118.35 6.55 Favored 'General case' 0 C--N 1.267 -3.003 0 CA-C-O 122.529 1.157 . . . . 0.0 111.576 -179.535 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.554 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.24 136.79 29.69 Favored Pre-proline 0 C--N 1.292 -1.929 0 CA-C-N 114.924 -1.034 . . . . 0.0 109.354 -179.296 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.7 Cg_endo -54.01 -13.28 4.41 Favored 'Trans proline' 0 C--N 1.306 -1.692 0 O-C-N 122.884 0.939 . . . . 0.0 110.575 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.44 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 0.2 OUTLIER -85.05 -27.92 26.02 Favored 'General case' 0 N--CA 1.492 1.64 0 CA-C-O 122.114 0.959 . . . . 0.0 109.33 177.529 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.554 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.26 40.7 p90 -173.08 159.67 3.98 Favored 'General case' 0 C--N 1.294 -1.82 0 N-CA-C 106.215 -1.772 . . . . 0.0 106.215 -178.769 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.717 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.3 OUTLIER -171.37 132.01 0.77 Allowed 'General case' 0 C--N 1.289 -2.063 0 C-N-CA 116.655 -2.018 . . . . 0.0 110.51 178.589 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.717 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.4 t -162.97 156.02 2.35 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.555 0 CA-C-O 121.777 0.799 . . . . 0.0 110.271 -179.357 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -131.58 128.63 39.6 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.643 -0.661 . . . . 0.0 110.08 -179.969 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.719 HG22 ' NH1' ' A' ' 18' ' ' ARG . 0.4 OUTLIER -165.57 131.8 0.5 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.377 0 O-C-N 121.483 -0.76 . . . . 0.0 109.432 179.999 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.462 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -172.7 109.32 0.3 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.516 -1.834 . . . . 0.0 108.516 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.719 ' NH1' HG22 ' A' ' 16' ' ' VAL . 0.0 OUTLIER . . . . . 0 C--N 1.295 -1.763 0 C-N-CA 117.886 -1.525 . . . . 0.0 111.841 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 13.0 ptp180 . . . . . 0 N--CA 1.493 1.687 0 CA-C-O 121.043 0.449 . . . . 0.0 110.179 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . 140.36 -30.79 2.3 Favored Glycine 0 N--CA 1.491 2.318 0 N-CA-C 109.561 -1.416 . . . . 0.0 109.561 -179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.443 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -148.4 115.09 0.72 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.514 -1.434 . . . . 0.0 109.514 179.791 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.642 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -129.21 104.76 7.72 Favored 'General case' 0 C--N 1.299 -1.623 0 C-N-CA 118.727 -1.189 . . . . 0.0 108.154 178.138 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.83 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -116.17 110.85 19.38 Favored 'General case' 0 C--N 1.291 -1.975 0 N-CA-C 108.371 -0.974 . . . . 0.0 108.371 179.569 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -146.58 120.38 9.27 Favored 'General case' 0 C--N 1.292 -1.918 0 CA-C-O 122.02 0.914 . . . . 0.0 110.298 -179.309 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -168.01 160.05 11.74 Favored 'General case' 0 C--N 1.295 -1.774 0 N-CA-C 107.984 -1.117 . . . . 0.0 107.984 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.8 t -148.43 118.56 7.25 Favored 'General case' 0 C--N 1.267 -2.985 0 CA-C-O 122.514 1.149 . . . . 0.0 111.565 -179.337 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.569 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.11 136.7 29.43 Favored Pre-proline 0 C--N 1.292 -1.901 0 CA-C-N 114.906 -1.043 . . . . 0.0 109.417 -179.309 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -54.72 -14.67 8.02 Favored 'Trans proline' 0 C--N 1.305 -1.739 0 O-C-N 122.791 0.89 . . . . 0.0 110.105 -179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.576 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 28.7 mmm-85 -84.71 -26.46 27.67 Favored 'General case' 0 N--CA 1.49 1.535 0 CA-C-O 122.099 0.952 . . . . 0.0 109.524 177.501 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.576 ' CD2' ' HB2' ' A' ' 11' ' ' ARG 0.253 41.6 p90 -173.63 158.89 3.46 Favored 'General case' 0 C--N 1.295 -1.763 0 N-CA-C 106.256 -1.757 . . . . 0.0 106.256 -179.276 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.746 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.3 OUTLIER -171.34 130.98 0.74 Allowed 'General case' 0 C--N 1.289 -2.061 0 C-N-CA 116.554 -2.058 . . . . 0.0 110.595 178.789 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.746 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.6 t -163.11 156.43 2.18 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.561 0 CA-C-O 121.746 0.784 . . . . 0.0 110.29 -179.503 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.453 ' C ' ' CG2' ' A' ' 16' ' ' VAL . 0.3 OUTLIER -131.73 118.99 20.71 Favored 'General case' 0 N--CA 1.491 1.621 0 CA-C-O 121.456 0.646 . . . . 0.0 109.969 179.931 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.453 ' CG2' ' C ' ' A' ' 15' ' ' CYS . 0.3 OUTLIER -153.69 121.92 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.775 0 O-C-N 121.473 -0.767 . . . . 0.0 109.326 179.745 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.488 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -166.56 105.21 0.24 Allowed Glycine 0 C--N 1.298 -1.573 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.293 -1.882 0 C-N-CA 118.166 -1.414 . . . . 0.0 111.224 -178.888 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . 0.471 ' CB ' ' HD2' ' A' ' 4' ' ' ARG . 0.1 OUTLIER . . . . . 0 N--CA 1.492 1.64 0 CA-C-O 121.198 0.523 . . . . 0.0 110.352 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -91.13 -61.53 1.26 Allowed Glycine 0 N--CA 1.493 2.463 0 N-CA-C 109.221 -1.552 . . . . 0.0 109.221 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . . . . . . . . . . . -153.13 119.87 1.0 Allowed Glycine 0 N--CA 1.487 2.093 0 N-CA-C 108.959 -1.656 . . . . 0.0 108.959 179.587 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.57 ' HA ' ' HA3' ' A' ' 17' ' ' GLY . 0.0 OUTLIER -145.5 104.68 3.93 Favored 'General case' 0 C--N 1.295 -1.79 0 C-N-CA 118.596 -1.242 . . . . 0.0 109.283 177.798 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.782 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.7 mm? -115.68 112.05 21.5 Favored 'General case' 0 C--N 1.291 -1.959 0 C-N-CA 119.612 -0.835 . . . . 0.0 108.867 179.152 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 0.1 OUTLIER -147.72 119.62 8.16 Favored 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 122.07 0.938 . . . . 0.0 110.149 -179.918 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.6 OUTLIER -168.84 160.65 10.48 Favored 'General case' 0 C--N 1.297 -1.702 0 N-CA-C 108.085 -1.08 . . . . 0.0 108.085 -178.52 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.0 t -148.03 118.02 7.21 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 122.641 1.21 . . . . 0.0 111.401 -179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.19 136.86 29.82 Favored Pre-proline 0 C--N 1.293 -1.859 0 CA-C-N 114.859 -1.064 . . . . 0.0 109.319 -179.169 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -17.2 9.36 Favored 'Trans proline' 0 C--N 1.306 -1.673 0 O-C-N 122.747 0.867 . . . . 0.0 110.133 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.584 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 12.9 mmt85 -80.96 -28.1 35.76 Favored 'General case' 0 N--CA 1.491 1.604 0 CA-C-O 121.981 0.896 . . . . 0.0 109.534 177.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.584 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.254 42.1 p90 -173.62 159.88 3.65 Favored 'General case' 0 C--N 1.296 -1.755 0 N-CA-C 106.435 -1.691 . . . . 0.0 106.435 -179.049 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.73 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.79 130.99 0.83 Allowed 'General case' 0 C--N 1.288 -2.067 0 C-N-CA 116.698 -2.001 . . . . 0.0 110.564 178.617 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.73 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.1 156.16 2.26 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.551 0 CA-C-O 121.663 0.744 . . . . 0.0 110.087 -179.404 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.506 ' C ' HG23 ' A' ' 16' ' ' VAL . 0.1 OUTLIER -132.36 119.69 21.05 Favored 'General case' 0 N--CA 1.492 1.627 0 CA-C-O 121.524 0.678 . . . . 0.0 110.308 179.972 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.506 HG23 ' C ' ' A' ' 15' ' ' CYS . 69.3 t -156.09 123.97 0.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.646 0 N-CA-C 109.044 -0.724 . . . . 0.0 109.044 179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.57 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -167.75 105.27 0.23 Allowed Glycine 0 C--N 1.299 -1.502 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.997 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.425 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.847 0 C-N-CA 118.404 -1.318 . . . . 0.0 111.112 -179.679 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.652 0 CA-C-O 121.123 0.487 . . . . 0.0 110.147 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -107.98 -27.3 5.18 Favored Glycine 0 N--CA 1.491 2.345 0 N-CA-C 109.812 -1.315 . . . . 0.0 109.812 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.402 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 170.32 135.42 1.91 Allowed Glycine 0 N--CA 1.49 2.269 0 N-CA-C 109.614 -1.394 . . . . 0.0 109.614 -179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.64 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -125.85 105.21 8.78 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 107.78 -1.193 . . . . 0.0 107.78 178.02 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.811 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.2 mm? -114.42 111.04 20.81 Favored 'General case' 0 C--N 1.289 -2.041 0 CA-C-O 121.859 0.837 . . . . 0.0 108.842 -179.797 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 4.7 t -151.65 121.43 7.02 Favored 'General case' 0 C--N 1.289 -2.032 0 CA-C-O 122.078 0.942 . . . . 0.0 110.215 -179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -167.92 160.76 12.5 Favored 'General case' 0 C--N 1.294 -1.813 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 -178.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.5 t -144.3 118.81 9.7 Favored 'General case' 0 C--N 1.265 -3.067 0 CA-C-O 122.529 1.157 . . . . 0.0 111.429 -179.415 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.558 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -128.99 136.71 29.6 Favored Pre-proline 0 C--N 1.292 -1.899 0 CA-C-N 114.921 -1.036 . . . . 0.0 109.203 -179.135 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.2 Cg_endo -54.03 -16.08 8.62 Favored 'Trans proline' 0 C--N 1.305 -1.723 0 O-C-N 122.772 0.88 . . . . 0.0 110.104 -179.284 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.475 ' HB2' ' CD2' ' A' ' 12' ' ' PHE . 66.9 mtp180 -82.36 -28.4 31.55 Favored 'General case' 0 N--CA 1.492 1.633 0 CA-C-O 122.103 0.954 . . . . 0.0 109.54 177.414 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.558 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.257 40.0 p90 -173.11 160.07 4.05 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 106.557 -1.645 . . . . 0.0 106.557 -178.594 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.752 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.5 OUTLIER -170.14 128.13 0.87 Allowed 'General case' 0 C--N 1.288 -2.082 0 C-N-CA 116.679 -2.009 . . . . 0.0 110.338 178.517 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.752 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.9 t -162.87 156.92 2.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 CA-C-O 121.646 0.736 . . . . 0.0 110.574 -179.143 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.51 ' C ' HG23 ' A' ' 16' ' ' VAL . 16.5 t -126.68 132.31 51.21 Favored 'General case' 0 N--CA 1.49 1.569 0 CA-C-O 121.572 0.701 . . . . 0.0 110.128 179.578 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.51 HG23 ' C ' ' A' ' 15' ' ' CYS . 92.3 t -156.15 131.94 1.8 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 108.811 -0.811 . . . . 0.0 108.811 179.898 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -164.35 106.46 0.27 Allowed Glycine 0 C--N 1.294 -1.803 0 N-CA-C 108.098 -2.001 . . . . 0.0 108.098 -179.968 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.453 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.294 -1.834 0 C-N-CA 118.509 -1.276 . . . . 0.0 111.393 -179.106 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.676 0 CA-C-O 121.197 0.522 . . . . 0.0 110.144 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -94.77 -33.3 6.76 Favored Glycine 0 N--CA 1.491 2.339 0 N-CA-C 109.781 -1.328 . . . . 0.0 109.781 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.437 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . 166.59 127.86 0.93 Allowed Glycine 0 N--CA 1.491 2.356 0 N-CA-C 110.13 -1.188 . . . . 0.0 110.13 -179.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.654 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -130.29 104.52 7.33 Favored 'General case' 0 C--N 1.301 -1.521 0 N-CA-C 107.718 -1.215 . . . . 0.0 107.718 177.522 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.814 HD22 ' N ' ' A' ' 5' ' ' LEU . 1.9 mm? -117.95 110.93 18.31 Favored 'General case' 0 C--N 1.29 -2.003 0 N-CA-C 108.629 -0.878 . . . . 0.0 108.629 179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . 0.465 ' HA ' ' HA ' ' A' ' 15' ' ' CYS . 52.1 t -153.5 122.03 6.29 Favored 'General case' 0 C--N 1.291 -1.94 0 CA-C-O 122.435 1.112 . . . . 0.0 110.585 -179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.5 OUTLIER -168.31 161.0 11.85 Favored 'General case' 0 C--N 1.294 -1.811 0 N-CA-C 107.423 -1.325 . . . . 0.0 107.423 -178.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 6.8 t -143.32 119.14 10.55 Favored 'General case' 0 C--N 1.265 -3.072 0 CA-C-O 122.598 1.19 . . . . 0.0 111.757 -179.186 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.562 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.05 136.31 28.99 Favored Pre-proline 0 C--N 1.292 -1.935 0 CA-C-N 114.785 -1.098 . . . . 0.0 109.056 -179.341 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.95 -15.79 7.91 Favored 'Trans proline' 0 C--N 1.305 -1.758 0 O-C-N 122.765 0.876 . . . . 0.0 110.142 -179.297 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.602 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 20.5 mmt85 -82.68 -27.31 31.36 Favored 'General case' 0 N--CA 1.49 1.549 0 CA-C-O 121.978 0.894 . . . . 0.0 109.525 177.545 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.602 ' CD1' ' HB2' ' A' ' 11' ' ' ARG 0.252 43.1 p90 -173.83 159.88 3.51 Favored 'General case' 0 C--N 1.295 -1.784 0 N-CA-C 106.513 -1.662 . . . . 0.0 106.513 -179.093 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.772 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.6 OUTLIER -170.14 127.68 0.85 Allowed 'General case' 0 C--N 1.289 -2.041 0 C-N-CA 116.642 -2.023 . . . . 0.0 110.569 178.593 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.772 HG23 ' O ' ' A' ' 13' ' ' CYS . 2.1 t -163.27 155.85 2.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 CA-C-O 121.465 0.65 . . . . 0.0 110.116 -179.19 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.495 ' C ' HG23 ' A' ' 16' ' ' VAL . 23.7 m -135.86 119.24 16.81 Favored 'General case' 0 N--CA 1.493 1.72 0 O-C-N 121.563 -0.711 . . . . 0.0 110.433 179.686 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.495 HG23 ' C ' ' A' ' 15' ' ' CYS . 95.8 t -152.17 124.94 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.447 0 CA-C-O 121.65 0.738 . . . . 0.0 109.083 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.477 ' HA3' ' HA ' ' A' ' 4' ' ' ARG . . . -165.24 107.88 0.31 Allowed Glycine 0 C--N 1.295 -1.702 0 N-CA-C 108.031 -2.028 . . . . 0.0 108.031 -179.793 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.449 ' N ' ' CD ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.292 -1.922 0 C-N-CA 118.392 -1.323 . . . . 0.0 111.664 -178.951 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.646 0 CA-C-O 121.114 0.483 . . . . 0.0 110.198 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -61.94 -51.24 58.43 Favored Glycine 0 N--CA 1.49 2.284 0 N-CA-C 109.94 -1.264 . . . . 0.0 109.94 -179.777 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' GLY . . . . . 0.431 ' C ' ' HD3' ' A' ' 4' ' ' ARG . . . -179.35 130.36 1.51 Allowed Glycine 0 N--CA 1.49 2.248 0 N-CA-C 109.95 -1.26 . . . . 0.0 109.95 -179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ARG . . . . . 0.649 ' C ' HD22 ' A' ' 5' ' ' LEU . 0.0 OUTLIER -128.39 105.23 8.18 Favored 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 177.673 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LEU . . . . . 0.82 HD22 ' N ' ' A' ' 5' ' ' LEU . 2.1 mm? -115.43 112.08 21.76 Favored 'General case' 0 C--N 1.291 -1.975 0 CA-C-O 121.922 0.868 . . . . 0.0 108.797 -179.689 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' CYS . . . . . . . . . . . . . 2.9 t -147.82 121.59 9.28 Favored 'General case' 0 C--N 1.291 -1.967 0 CA-C-O 122.042 0.925 . . . . 0.0 110.221 -179.717 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' TYR . . . . . . . . . . . . . 0.4 OUTLIER -167.42 160.16 13.02 Favored 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 -178.633 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 8.4 t -149.77 118.87 6.73 Favored 'General case' 0 C--N 1.267 -2.986 0 CA-C-O 122.554 1.168 . . . . 0.0 111.607 -179.252 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' ARG . . . . . 0.577 ' O ' ' O ' ' A' ' 12' ' ' PHE . 0.0 OUTLIER -129.16 136.54 29.32 Favored Pre-proline 0 C--N 1.293 -1.886 0 CA-C-N 114.901 -1.045 . . . . 0.0 109.246 -179.377 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -53.64 -16.68 8.45 Favored 'Trans proline' 0 C--N 1.305 -1.713 0 O-C-N 122.726 0.856 . . . . 0.0 110.311 -179.263 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ARG . . . . . 0.499 ' HB2' ' CD1' ' A' ' 12' ' ' PHE . 27.0 mtp180 -81.28 -28.44 34.69 Favored 'General case' 0 N--CA 1.491 1.579 0 CA-C-O 122.143 0.973 . . . . 0.0 109.54 177.522 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' PHE . . . . . 0.577 ' O ' ' O ' ' A' ' 9' ' ' ARG 0.259 41.1 p90 -173.19 159.5 3.87 Favored 'General case' 0 C--N 1.294 -1.836 0 N-CA-C 106.331 -1.729 . . . . 0.0 106.331 -178.788 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' CYS . . . . . 0.747 ' O ' HG23 ' A' ' 14' ' ' VAL . 0.2 OUTLIER -170.56 131.05 0.89 Allowed 'General case' 0 C--N 1.288 -2.095 0 C-N-CA 116.577 -2.049 . . . . 0.0 110.571 178.657 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.747 HG23 ' O ' ' A' ' 13' ' ' CYS . 1.5 t -163.92 156.47 1.93 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.49 0 CA-C-O 121.711 0.767 . . . . 0.0 110.163 -179.308 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' CYS . . . . . 0.504 ' C ' HG23 ' A' ' 16' ' ' VAL . 48.9 t -133.48 131.2 39.59 Favored 'General case' 0 N--CA 1.49 1.559 0 CA-C-O 121.592 0.71 . . . . 0.0 110.347 179.657 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . 0.504 HG23 ' C ' ' A' ' 15' ' ' CYS . 70.8 t -156.6 128.55 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.577 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 179.822 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -165.23 106.23 0.26 Allowed Glycine 0 C--N 1.295 -1.715 0 N-CA-C 108.042 -2.023 . . . . 0.0 108.042 -179.977 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ARG . . . . . 0.524 ' N ' ' NE ' ' A' ' 18' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.293 -1.85 0 C-N-CA 118.418 -1.313 . . . . 0.0 111.251 -179.28 . . . . . . . . 2 2 . 1 stop_ save_